30.1.2020

AMENDMENTS
1 - 258

Draft motion for a resolution
Cristian-Silviu Bușoi, Günther Sidl, Jan Huitema, Michèle Rivasi, Simona Baldassarre, Joanna Kopcińska, Kateřina Konečná
(PE641.393v02-00)

Strategic approach to pharmaceuticals in the environment
(2019/2816(RSP))
Amendment 1
Günther Sidl, Tiemo Wölken, Nicolás González Casares, Mohammed Chahim, César Luena, Eric Andrieu, Biljana Borzan

Draft motion for a resolution
Citation 1 a (new)

Draft motion for a resolution Amendment
- having regard to Article 191 (2) of the Treaty on the Functioning of the European Union, on the polluter pays principle, the precautionary principle and control at source principle,

Or. en

Amendment 2
Jan Huitema

Draft motion for a resolution
Citation 1 a (new)

Draft motion for a resolution Amendment
- having regard to Article 191 (2) of the Treaty on the Functioning of the European Union,

Or. en

Amendment 3
Adam Jarubas

Draft motion for a resolution
Citation 1 a (new)

Draft motion for a resolution Amendment
- having regard to Article 191 (2) of the Treaty on the Functioning of the European Union,

Or. en
Amendment 4
Joanna Kopcińska, Jadwiga Wiśniewska

Draft motion for a resolution
Citation 1 a (new)

Draft motion for a resolution

Amendment

- having regard to Article 191 (2) of the Treaty on the Functioning of the European Union,

Or. en

Amendment 5
Michèle Rivasi

Draft motion for a resolution
Citation 1 a (new)

Draft motion for a resolution

Amendment

- having regard to Article 191 (2) of the Treaty on the Functioning of the European Union,

Or. en

Amendment 6
Stanislav Polčák

Draft motion for a resolution
Citation 1 a (new)

Draft motion for a resolution

Amendment

– having regard to Article 11 of the Treaty on the Functioning of the European Union,

Or. cs
Amendment 7
Stanislav Polčák

Draft motion for a resolution
Citation 1 b (new)

Draft motion for a resolution

Amendment

– having regard to Article 191 of the
Treaty on the Functioning of the
European Union,

Or. cs

Amendment 8
Stanislav Polčák

Draft motion for a resolution
Citation 1 c (new)

Draft motion for a resolution

Amendment

– having regard to the 7th
Environment Action Programme to 2020
‘Living well, within the limits of our planet’, as adopted by Decision
1386/2013/EU of the European Parliament and of the Council of 20
November 2013,

Or. cs

Amendment 9
Jan Huitema

Draft motion for a resolution
Citation 8 a (new)

Draft motion for a resolution

Amendment

– having regard to the successive
annual European Surveillance of
Veterinary Antimicrobial Consumption
(ESVAC) reports (since 2011),
Amendment 10
Catherine Chabaud

Draft motion for a resolution
Citation 9 a (new)

Draft motion for a resolution
Amendment
- having regard to Directive 2008/56/CE on the Marine Strategic Framework,

Or. en

Amendment 11
Cristian-Silviu Bușoi

Draft motion for a resolution
Citation 10 a (new)

Draft motion for a resolution
Amendment
- having regard to the Council conclusions of 24 June 2019 on the next steps towards making the EU a best practice region in combatting antimicrobial resistance,

Or. en

Amendment 12
Eleonora Evi, Daniela Rondinelli, Piernicola Pedicini

Draft motion for a resolution
Citation 12 a (new)

Draft motion for a resolution
Amendment
- having regard to the Council Conclusions of 26 June 2019 on the next steps towards making the EU a best practice region in combatting
Draft motion for a resolution
Citation 26 a (new)

Draft motion for a resolution
Amendment

- having regard to the Council conclusions of 24 June 2019 on the next steps towards making the EU a best practice region in combatting antimicrobial resistance,

Draft motion for a resolution
Amendment

- having regard to the Council conclusions of 24 June 2019 on the next steps towards making the EU a best practice region in combatting antimicrobial resistance,
Draft motion for a resolution

Amendment

- having regard to the Commission Communication of the 11 December 2019 entitled ‘European Green Deal’ (COM(2019) 640) and the Resolution of the Parliament of 15 January 2020 in response,

Or. en

Amendment 16
Günther Sidl, Tiemo Wölken, Nicolás González Casares, Mohammed Chahim, César Luena, Eric Andrieu, Biljana Borzan

Draft motion for a resolution
Citation 12 a (new)

Draft motion for a resolution

Amendment

- having regard to the Commission Communication of the 11 December 2019 entitled “European Green Deal” (COM(2019)640),

Or. en

Amendment 17
Cristian-Silviu Bușoi

Draft motion for a resolution
Citation 17 a (new)

Draft motion for a resolution

Amendment

- having regard to the Commission Communication of the 11 December 2019 entitled ‘European Green Deal’ (COM(2019) 640),

Or. en

Amendment 18
Kateřina Konečná

Draft motion for a resolution
Citation 17 a (new)

Draft motion for a resolution

Draft motion for a resolution
Amendment
- having regard to the Commission Communication of the 11 December 2019 entitled ‘European Green Deal’ (COM(2019) 640),

Or. en

Amendment 19
Adam Jarubas

Draft motion for a resolution
Citation 17 a (new)

Draft motion for a resolution
Amendment
- having regard to the Commission Communication of the 11 December 2019 entitled ‘European Green Deal’ (COM(2019) 640),

Or. en

Amendment 20
Jan Huitema

Draft motion for a resolution
Citation 17 a (new)

Draft motion for a resolution
Amendment
- having regard to the Commission Communication 'European Green Deal' (COM(2019) 640) of the 11 December 2019,

Or. en
Amendment 21
Nathalie Colin-Oesterlé

Draft motion for a resolution
Citation 26 a (new)

Draft motion for a resolution Amendment

- having regard to the Commission Communication of 11 December 2019 entitled ‘The European Green Deal’ (COM(2019)0640),

Or. fr

Amendment 22
Günther Sidl, Tiemo Wölken, Nicolás González Casares, Mohammed Chahim, César Luena, Eric Andrieu, Biljana Borzan

Draft motion for a resolution
Citation 12 b (new)

Draft motion for a resolution Amendment

- having regard to its resolution of 15 January 2020 on the European Green Deal (2019/2956(RSP)),

Or. en

Amendment 23
Esther de Lange

Draft motion for a resolution
Citation 18 a (new)

Draft motion for a resolution Amendment

- having regard to several Member States' programmes such as the Netherlands Chain approach to reduce pharmaceutical residues in water;

Or. en
Amendment 24
Günther Sidl, Tiemo Wölken, Nicolás González Casares, Mohammed Chahim, César Luena, Eric Andrieu, Biljana Borzan

Draft motion for a resolution
Citation 21 a (new)

Draft motion for a resolution

Amendment

- having regard to the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) Regulation (EC) No 1907/2006,

Or. en

Amendment 25
Michèle Rivasi

Draft motion for a resolution
Citation 22 a (new)

Draft motion for a resolution

Amendment

- having regard to the OECD study of November 2019 "Pharmaceutical Residues in Freshwater - Hazards and Policy Responses"7a,


Or. en

Amendment 26
Kateřina Konečná

Draft motion for a resolution
Citation 22 a (new)
Draft motion for a resolution

- having regard to the OECD study of November 2019 Pharmaceutical Residues in Freshwater - Hazards and Policy Responses,

Or. en

Amendment 27
Cristian-Silviu Buşoi

Draft motion for a resolution
Citation 22 a (new)

- having regard to the OECD study of November 2019 Pharmaceutical Residues in Freshwater - Hazards and Policy Responses,

Or. en

Amendment 28
Adam Jarubas

Draft motion for a resolution
Citation 22 a (new)

- having regard to the OECD study of November 2019 Pharmaceutical Residues in Freshwater - Hazards and Policy Responses,

Or. en

Amendment 29
Jan Huitema

Draft motion for a resolution
Citation 23 a (new)

Draft motion for a resolution
Amendment

- having regard to the OECD study
'Pharmaceutical Residues in Freshwater - Hazards and Policy Responses' of November 2019,

Or. en

Amendment 30
Günther Sidl, Tiemo Wölken, Nicolás González Casares, Mohammed Chahim, César Luena, Eric Andrieu, Biljana Borzan

Draft motion for a resolution
Citation 23 a (new)

Draft motion for a resolution
Amendment

- having regard to the OECD study of November 2019 Pharmaceutical Residues in Freshwater - Hazards and Policy Responses,

Or. en

Amendment 31
Joanna Kopcińska, Jadwiga Wiśniewska

Draft motion for a resolution
Citation 12 a (new)

Draft motion for a resolution
Amendment

- having regard to the OECD study of November 2019 Pharmaceutical Residues in Freshwater - Hazards and Policy Responses,

Or. en

Amendment 32
Draft motion for a resolution

Citation 24 a (new)

Draft motion for a resolution

Amendment

— having regard to the Commission document entitled 'Towards a sustainable Europe by 2030',

Or. cs

Amendment 33
Mairead McGuinness

Draft motion for a resolution
Recital A

Draft motion for a resolution

Amendment

A. whereas pharmaceuticals play an essential role in ensuring a high level of public health; whereas there are currently more than 3000 active pharmaceutical ingredients on the European market;

Or. en

Amendment 34
Jan Huitema, Ulrike Müller

Draft motion for a resolution
Recital B

Draft motion for a resolution

Amendment

B. whereas the wide use of pharmaceuticals in human and veterinary medicines, including antimicrobial agents, has increased their concentrations in many environmental reservoirs such as soils, sediments and waterbodies in the past 20 years; whereas the largest source of

population grows and
Amendment 35
Esther de Lange

Draft motion for a resolution
Recital B

B. whereas the wide use of pharmaceuticals in human and veterinary medicines, including antimicrobial agents, has increased their concentrations in many environmental reservoirs such as soils, sediments and waterbodies in the past 20 years; whereas the largest source of pharmaceuticals entering the environment is their use and disposal; whereas the impact of climate change will affect both the quantity and the quality of water resources as at times of drought concentrations will be higher; whereas there is a need for more widespread gathering to measure this problem around the world; whereas the largest source of pharmaceuticals entering the environment is their use and disposal;

Or. en

Amendment 36
Anja Hazekamp

Draft motion for a resolution
Recital B

B. whereas the wide use of pharmaceuticals in human and veterinary medicines, including antimicrobial agents, has increased their concentrations in many environmental reservoirs such as soils, sediments and waterbodies in the past 20 years; whereas environmental concentrations are likely to increase as the population ages and grows, and climate change is expected to worsen the pollution of water by pharmaceutical residues as at times of drought concentrations will be higher; whereas the largest source of pharmaceuticals entering the environment is their use and disposal;

Or. en
B. whereas the wide use of pharmaceuticals in human and veterinary medicines, including antimicrobial agents, has increased their concentrations in many environmental reservoirs such as soils, sediments and waterbodies in the past 20 years; whereas the largest source of pharmaceuticals entering the environment is their use and disposal;
Amendment 38
Stanislav Polčák

Draft motion for a resolution
Recital B

Draft motion for a resolution

B. whereas the wide use of pharmaceuticals in human and veterinary medicines, including antimicrobial agents, has increased their concentrations in many environmental reservoirs such as soils, sediments and waterbodies in the past 20 years; whereas the largest source of pharmaceuticals entering the environment is their use and disposal;

Amendment

B. whereas the wide use of active substances in human and veterinary medicines, including antimicrobial agents, has increased their concentrations in many environmental reservoirs such as soils, sediments and waterbodies in the past 20 years; whereas the trend towards increasing consumption of pharmaceuticals for human use is likely to continue as the population gradually ages and grows; whereas the largest source of pharmaceuticals entering the environment is their use and disposal;

Or. cs

Amendment 39
Michèle Rivasi

Draft motion for a resolution
Recital B

Draft motion for a resolution

B. whereas the wide use of pharmaceuticals in human and veterinary medicines, including antimicrobial agents, has increased their concentrations in many environmental reservoirs such as soils, sediments and waterbodies in the past 20 years; whereas the largest source of pharmaceuticals entering the environment is their use and disposal;

Amendment

B. whereas the wide use of pharmaceuticals in human and veterinary medicines, including antimicrobial agents, has increased their concentrations in many environmental reservoirs such as soils, sediments and waterbodies in the past 20 years; whereas environmental concentrations are likely to increase further as the population grows and ages; whereas the largest source of pharmaceuticals entering the environment is their use and disposal;
Amendment 40
Joanna Kopcińska, Jadwiga Wiśniewska

Draft motion for a resolution
Recital B

Draft motion for a resolution
Amendment

B. whereas the wide use of pharmaceuticals in human and veterinary medicines, including antimicrobial agents, has increased their concentrations in many environmental reservoirs such as soils, sediments and waterbodies in the past 20 years; whereas the largest source of pharmaceuticals entering the environment is their use and disposal;

Or. en

Amendment 41
Tudor Ciuhodaru

Draft motion for a resolution
Recital B

Draft motion for a resolution
Amendment

B. whereas the wide use of pharmaceuticals in human and veterinary medicines, including antimicrobial agents, has increased their concentrations in many environmental reservoirs such as soils, sediments and waterbodies in the past 20 years; whereas with changes to the size and age of population this trend may increase; whereas the largest source of pharmaceuticals entering the environment is their use and disposal;

Or. en

Or. ro
Amendment 42
Tudor Ciuhodaru

Draft motion for a resolution
Recital C

Draft motion for a resolution

C. whereas pharmaceuticals reach the environment through the discharge of effluent from urban wastewater treatment plants, the spreading of animal manure and aquaculture, discharge of effluent from manufacturing plants, the spreading of sewage sludge, grazing livestock, the treatment of pets, improper disposal into landfill of unused pharmaceuticals and contaminated waste;

Amendment

C. whereas pharmaceuticals reach the environment through the discharge of effluent from urban wastewater treatment plants, the spreading of animal manure and aquaculture, discharge of effluent from manufacturing plants, the spreading of sewage sludge, grazing livestock, the treatment of pets, improper disposal into landfill of unused pharmaceuticals and contaminated waste and their further dissemination by sometimes heavy rainfall;

Or. ro

Amendment 43
Nathalie Colin-Oesterlé

Draft motion for a resolution
Recital C a (new)

Draft motion for a resolution

Ca. whereas population increase and climate change will have an impact on the quantity of quality of water resources and on water treatment and re-use;

Amendment

Ca. whereas population increase and climate change will have an impact on the quantity of quality of water resources and on water treatment and re-use;

Or. fr

Amendment 44
Anja Hazekamp, Kateřina Konečná

Draft motion for a resolution
Recital D

AM\1197641EN.docx 19/111 PE646.955v01-00
Draft motion for a resolution

D. whereas the excessive and incorrect use of antibiotics, particularly in livestock farming, and more generally poor practices in both human and veterinary medicine, have progressively rendered antimicrobial resistance a massive threat to human and animal health;

Amendment

D. whereas the excessive and incorrect use of antibiotics, particularly in livestock farming, and more generally poor practices in both human and veterinary medicine, have progressively rendered antimicrobial resistance a massive threat to human and animal health; whereas intensive livestock farming, where large numbers of animals are kept in close proximity to each other, leads to the excessive use of veterinary medicines including antibiotics;

Or. nl

Amendment 45
Jan Huitema, Ulrike Müller, Fredrick Federley

Draft motion for a resolution
Recital D

Draft motion for a resolution

D. whereas the excessive and incorrect use of antibiotics, particularly in livestock farming, and more generally poor practices in both human and veterinary medicine, have progressively rendered antimicrobial resistance a massive threat to human and animal health;

Amendment

D. whereas the inappropriate use of antibiotics, and generally poor practices in both human and veterinary medicine, have progressively rendered antimicrobial resistance a massive threat to human and animal health;

Or. en

Amendment 46
Alexander Bernhuber

Draft motion for a resolution
Recital D

Draft motion for a resolution

D. whereas the excessive and incorrect use of antibiotics, particularly in livestock farming, and more generally poor practices in both human and veterinary medicine, have progressively rendered antimicrobial resistance a massive threat to human and animal health;

Amendment

D. whereas the incorrect use of antibiotics through generally poor
farming, and more generally poor practices in both human and veterinary medicine, **have** progressively rendered antimicrobial resistance a massive threat to human and animal health;

practices in both human and veterinary medicine, **particularly in non-EU countries, has** progressively rendered antimicrobial resistance a massive threat to human and animal health;

Or. de

Amendment 47
Nathalie Colin-Oesterlé

Draft motion for a resolution
Recital D

Draft motion for a resolution
Amendment

D. whereas the excessive and incorrect use of antibiotics, particularly in livestock farming, and more generally poor practices in both human and veterinary medicine, have progressively rendered antimicrobial resistance a massive threat to human and animal health;

D. whereas the **inappropriate** use of antibiotics, particularly in livestock farming, and more generally poor practices in both human and veterinary medicine, have progressively rendered antimicrobial resistance a massive threat to human and animal health;

Or. fr

Amendment 48
Maria Spyraiki, Vangelis Meimarakis, Elissavet Vozemberg-Vrionidi, Georgios Kyrtos, Anna-Michelle Asimakopoulou

Draft motion for a resolution
Recital D

Draft motion for a resolution
Amendment

D. whereas the excessive and incorrect use of antibiotics, particularly in livestock farming, and more generally poor practices in both human and veterinary medicine, have progressively rendered antimicrobial resistance a massive threat to human and animal health;

D. whereas the **inefficient** use of antibiotics, particularly in livestock farming, and more generally poor practices in both human and veterinary medicine, have progressively rendered antimicrobial resistance a massive threat to human and animal health;

Or. en
Amendment 49
Michèle Rivasi

Draft motion for a resolution
Recital D a (new)

Draft motion for a resolution

Amendment

D a. whereas the OECD in its latest report on pharmaceutical residues in freshwater found that "current policy approaches to manage pharmaceutical residues are inadequate for the protection of water quality and freshwater ecosystems upon which health lives depend";

Or. en

Amendment 50
Stanislav Polčák

Draft motion for a resolution
Recital D a (new)

Draft motion for a resolution

Amendment

D a. whereas the chemical and/or metabolic stability of certain pharmaceuticals means that up to 90 % of their active substances are released into the environment in their original form after use;

Or. cs

Amendment 51
Joëlle Mélin, Annika Bruna, Catherine Griset, Luisa Regimenti

Draft motion for a resolution
Recital D a (new)

Draft motion for a resolution

Amendment
Da. whereas there is a lack of studies on the mutual potentiation of the different molecules and the interaction of their natural metabolic degradation products;

Amendment 52
Kateřina Konečná

Draft motion for a resolution
Recital D a (new)

Draft motion for a resolution
Amendment

D a. whereas the veterinary antibiotics (VAs) are used in large amounts for therapeutic and prophylactic purposes in addition to their application as growth promoters;

Amendment 53
Jan Huitema, Ulrike Müller

Draft motion for a resolution
Recital E

Draft motion for a resolution
Amendment

E. whereas pharmaceuticals put on the market before 2006 were not subject to an environmental risk assessment as part of the authorisation process and might therefore still lack such an assessment;

E. whereas pharmaceuticals authorised for human use and put on the market before 2006 were not subject to an environmental risk assessment as part of the authorisation process and might therefore still lack such an assessment;

Amendment 54
Esther de Lange
Draft motion for a resolution
Recital E

E. whereas pharmaceuticals put on the market before 2006 were not subject to an environmental risk assessment as part of the authorisation process and might therefore still lack such an assessment;

Amendment

E. whereas pharmaceuticals authorised for human use and put on the market before 2006 were not subject to an environmental risk assessment as part of the authorisation process and might therefore still lack such an assessment;

Or. en

Amendment 55
Cristian-Silviu Buşoi

Draft motion for a resolution
Recital E

E. whereas pharmaceuticals put on the market before 2006 were not subject to an environmental risk assessment as part of the authorisation process and might therefore still lack such an assessment;

Amendment

E. whereas pharmaceuticals authorised for human use put on the market before 2006 were not subject to an environmental risk assessment as part of the authorisation process and might therefore still lack such an assessment;

Or. en

Amendment 56
Stanislav Polčák

Draft motion for a resolution
Recital F a (new)

F a. whereas, in its proposed communication, the Commission itself acknowledges the knowledge gaps in terms of concentrations of certain pharmaceuticals in the environment and the resulting levels of risk;

Amendment


Amendment 57
Jan Huitema, Ulrike Müller

Draft motion for a resolution
Recital G

Draft motion for a resolution

G. whereas there is sufficient evidence that action should be taken to reduce the risk from pharmaceuticals in the environment;

Amendment

G. whereas there is sufficient evidence that action should be taken to reduce the negative environmental impact from some pharmaceuticals, especially their impact on the development and spread of antimicrobial resistance;

Amendment 58
Joanna Kopcińska, Jadwiga Wiśniewska

Draft motion for a resolution
Recital G

Draft motion for a resolution

G. whereas there is sufficient evidence that action should be taken to reduce the risk from pharmaceuticals in the environment;

Amendment

G. whereas there is sufficient evidence that action should be taken to reduce the risk from pharmaceuticals in the environment; including the protection of water resources in line with the Water Framework Directive

Amendment 59
Michèle Rivasi

Draft motion for a resolution
Recital G

Draft motion for a resolution

G. whereas there is sufficient evidence that action should be taken to reduce the risk from pharmaceuticals in the environment;
G. whereas there is sufficient evidence that action should be taken to reduce the risk from pharmaceuticals in the environment;
Günther Sidl, Tiemo Wölken, Nicolás González Casares, Mohammed Chahim, César Luena, Eric Andrieu, Biljana Borzan, Demetris Papadakis

Draft motion for a resolution
Recital G

G. whereas there is sufficient evidence that action should be taken to reduce the risk from pharmaceuticals in the environment;

Amendment
G. whereas there is sufficient evidence that action should be taken to reduce the risk from pharmaceuticals in the environment, such as the impact on drinking water sources;

Amendment 63
Esther de Lange

Draft motion for a resolution
Recital H

H. whereas the environmental impact of pharmaceuticals has been recognised as an issue of concern by a large number of international organisations, third countries, European institutions, industry associations and Non-Governmental Organisations;

Amendment
H. whereas the environmental impact of pharmaceuticals has been recognised as an issue of concern by a large number of international organisations, third countries, European institutions, industry associations and Non-Governmental Organisations; whereas some EU Member States such as the Netherlands, Germany and Sweden have already taken action to address the growing presence of pharmaceuticals in the environment;

Amendment 64
Jan Huitema, Ulrike Müller

Draft motion for a resolution
Recital H
Draft motion for a resolution

H. whereas the environmental impact of pharmaceuticals has been recognised as an issue of concern by a large number of international organisations, third countries, European institutions, industry associations and Non-Governmental Organisations;

whereas Germany, Sweden and the Netherlands have already taken action to address the growing presence of pharmaceuticals in the environment;

Amendment

H. whereas the environmental impact of pharmaceuticals has been recognised as an issue of concern by a large number of international organisations, third countries, European institutions, industry associations and Non-Governmental Organisations;

whereas Germany, Sweden and the Netherlands have already taken action to address the growing presence of pharmaceuticals in the environment;

Or. en

Amendment 65
Michèle Rivasi

Draft motion for a resolution
Recital I

Draft motion for a resolution

I. whereas the Commission had committed to propose measures to reduce the potentially harmful impacts of pharmaceuticals on the environment in 2008;

_________________


Amendment

I. whereas the Commission had committed to propose measures to reduce the potentially harmful impacts of pharmaceuticals on the environment already in 2008;

_________________


Or. en

Amendment 66
Jan Huitema, Ulrike Müller

Draft motion for a resolution
Recital K
Draft motion for a resolution

K. whereas in its conclusions of June 2019, the Council called upon the Commission “to assess and define the most effective measures, including legislative measures, to mitigate the effects of pharmaceuticals in the environment and to combat the development of antimicrobial resistance and to reinforce the link with the health sector in this regard”;

Amendment

K. whereas in its conclusions of June 2019, the Council called upon the Commission “to assess and define the most effective measures, including legislative measures, to mitigate the effects of pharmaceuticals in the environment and to combat the development of antimicrobial resistance and to reinforce the link with the health sector in this regard”; whereas the Council acknowledged that further research is required to better understand the extent of the emerging human health and environmental impact of pharmaceuticals and their residues;

Or. en

Amendment 67
Günther Sidl, Tiemo Wölken, Nicolás González Casares, Mohammed Chahim, César Luena, Eric Andrieu, Biljana Borzan, Demetris Papadakis

Draft motion for a resolution
Recital L

Draft motion for a resolution

L. whereas there is self-regulation to limit the negative impact of pharmaceuticals in the environment, such as iPiE (Intelligent Assessment of Pharmaceuticals in the Environment);

Amendment

L. whereas there is self-regulation to limit the negative impact of pharmaceuticals in the environment, such as iPiE (Intelligent Assessment of Pharmaceuticals in the Environment);

Or. en

Amendment 68
Cristian-Silviu Bușoi

Draft motion for a resolution
Recital L

Draft motion for a resolution

L. whereas there is self-regulation to

Amendment

L. whereas there is self-regulation to

Or. en
limit the negative impact of pharmaceuticals in the environment, such as iPiE (Intelligent Assessment of Pharmaceuticals in the Environment);

Amendment 69
Eleonora Evi, Daniela Rondinelli, Piernicola Pedicini

Draft motion for a resolution
Recital L

Draft motion for a resolution
Amendment

L. whereas there is self-regulation to limit the negative impact of pharmaceuticals in the environment, such as iPiE (Intelligent Assessment of Pharmaceuticals in the Environment);

L. whereas the iPiE (Intelligent Assessment of Pharmaceuticals in the Environment) Project aims at developing a framework that will provide methodologies to prioritise new and existing medicinal compounds for a comprehensive environmental risk assessment;

Amendment 70
Michèle Rivasi

Draft motion for a resolution
Recital L

Draft motion for a resolution
Amendment

L. whereas there is self-regulation to limit the negative impact of pharmaceuticals in the environment, such as iPiE (Intelligent Assessment of Pharmaceuticals in the Environment);

L. whereas the project iPiE (Intelligent Assessment of Pharmaceuticals in the Environment) to prioritise new and existing medicinal compounds for a comprehensive environmental risk assessment was concluded in June 2019;
Amendment 71
Jan Huitema, Ulrike Müller

Draft motion for a resolution
Recital L a (new)

Draft motion for a resolution

Amendment

L a. whereas the AMR Industry Alliance has developed industry-driven principles of the Common Antibiotic Manufacturing Framework and determined targets for antibiotic discharge concentration in order to protect ecological resources and lower the potential risk of AMR development in the environment;

Or. en

Amendment 72
Nathalie Colin-Oesterlé

Draft motion for a resolution
Recital L a (new)

Draft motion for a resolution

Amendment

L a. whereas human and animal health players and professionals, patients, industry, waste management and water treatment operators, etc., have a role to play in reducing the impact of pharmaceutical products on the environment;

Or. fr

Amendment 73
Michèle Rivasi

Draft motion for a resolution
Recital L a (new)
L a. whereas the OECD advocates four proactive strategies with a focus on preventive options early in a pharmaceutical's life cycle to cost-effectively manage pharmaceuticals in the environment and to deliver the most long-term and large-scale environmental benefits;

Amendment 74
Jan Huitema, Ulrike Müller

Draft motion for a resolution
Recital L b (new)

L b. whereas the Pharmaceutical Supply Chain Initiative (PSCI) has been launched to define, implement and improve responsible supply chain practices, including to minimise negative impacts on the environment;

Amendment 75
Jan Huitema, Ulrike Müller

Draft motion for a resolution
Recital L c (new)

L c. whereas a campaign was launched by several stakeholders to raise awareness on how to dispose of unused or expired medicines appropriately in Europe as part of the #MedsDisposal initiative;
Amendment 76
Alessandra Moretti

Draft motion for a resolution
Subheading 1 a (new)

*Ia.* whereas any measure regarding the environmental impact of drugs shall consider as the prevailing principle the right of the patients to a swift access to drugs deemed safe and effective with respect to the current risk-benefit assessment criteria;

Amendment

Or. en

Amendment 77
Maria Spyraki, Vangelis Meimarakis, Elissavet Vozemberg-Vrionidi, Georgios Kyrtsos, Anna-Michelle Asimakopoulou

Draft motion for a resolution
Paragraph 3

3. *Notes however with concern the very* soft nature of the *measures* included in the communication; considers that *legislative* measures are needed *in addition to non-legislative measures to properly tackle pharmaceutical pollution*;

3. *Takes note of the soft nature of the recommendations* included in the communication *as these are driven by objectives to pursue, whereas the measures to be taken are of member state competence*; considers that *effective measures are needed to mitigate the impacts of pharmaceuticals in the environment*;

Or. en

Amendment 78
Cristian-Silviu Bușoi

Draft motion for a resolution
Paragraph 3

3. **Notes however with concern the** very soft nature of the measures included in the communication; considers that legislative measures are needed in addition to non-legislative measures to properly tackle pharmaceutical pollution;

Amendment 79
Jan Huitema, Ulrike Müller, Fredrick Federley

Draft motion for a resolution
Paragraph 3

3. **Notes however with concern the** very soft nature of the measures included in the communication; considers that legislative measures are needed in addition to non-legislative measures to properly tackle pharmaceutical pollution;

Amendment 80
Tudor Ciuhodaru

Draft motion for a resolution
Paragraph 3

3. Notes however with concern the very soft nature of the measures included in the communication; considers that legislative measures are needed in addition to non-legislative measures to properly tackle pharmaceutical pollution;
to non-legislative measures to properly tackle pharmaceutical pollution; to non-legislative measures to properly tackle pharmaceutical pollution at European level;

Amendment 81
Adam Jarubas

Draft motion for a resolution
Paragraph 3

Draft motion for a resolution

Amendment

3. Notes however with concern the very soft nature of the measures included in the communication; considers that legislative measures are needed in addition to non-legislative measures to properly tackle pharmaceutical pollution;

3. Notes however with concern the very soft nature of the measures included in the communication; considers that effective measures are needed to properly tackle pharmaceutical pollution, reflecting member state competences;

Amendment 82
Anja Hazekamp, Kateřina Konečná

Draft motion for a resolution
Paragraph 4

Draft motion for a resolution

Amendment

4. Recalls that any future initiatives in the field of the environmental impact of pharmaceuticals should be science and target driven, as well as technology neutral, making sure that safety and efficacy still remain key priority features for access for patients to pharmaceutical treatments;

4. Recalls that any future initiatives in the field of the environmental impact of pharmaceuticals should be based on the precautionary principle, target driven and technology neutral, making sure that safety and efficacy still remain key priority features for access for patients to pharmaceutical treatments;

Amendment 83

AM\1197641EN.docx 35/111 PE646.955v01-00
Draft motion for a resolution
Paragraph 5

Draft motion for a resolution

5. Considers that a holistic approach is needed to tackle pharmaceutical pollution, taking into account the entire life cycle of drugs; stresses that regulatory actions have to be taken in line with the precautionary principle; highlights that the polluter pays principle should apply, primarily covering the manufacturing process, but also incentivising better prescription practices and consumer behaviour;

Amendment

5. Considers that a holistic approach is needed to tackle pharmaceutical pollution at source, taking into account the entire life cycle of drugs; notes with concern the role that pharmaceuticals play in contributing to antimicrobial resistance when released into the environment via the discharge of animal manure, water pollution or improper disposal; stresses that regulatory actions have to be taken in line with the precautionary principle and the control at source principle; highlights that the polluter pays principle should apply, primarily covering the manufacturing process, but also incentivising better prescription practices and consumer behaviour;

Or. en

Amendment 84
Michèle Rivasi

Draft motion for a resolution
Paragraph 5

Draft motion for a resolution

5. Considers that a holistic approach is needed to tackle pharmaceutical pollution, taking into account the entire life cycle of drugs; stresses that regulatory actions have to be taken in line with the precautionary principle; highlights that the polluter pays principle should apply, primarily covering the manufacturing process, but also incentivising better prescription practices and consumer behaviour;

Amendment

5. Considers that a holistic approach is needed to tackle pharmaceutical pollution, taking into account the entire life cycle of drugs; stresses that regulatory actions have to be taken in particular at source, in line with the precautionary principle and the principle that environmental damage should as a priority be rectified at source; highlights that the polluter pays principle as well as extended producer responsibility should be applied, covering
all the stages of the life cycle, while also incentivising better prescription practices and responsible consumer behaviour;

Amendment 85  
Nathalie Colin-Oesterlé

Draft motion for a resolution  
Paragraph 5

Draft motion for a resolution

5. Considers that a holistic approach is needed to tackle pharmaceutical pollution, taking into account the entire life cycle of drugs; stresses that regulatory actions have to be taken in line with the precautionary principle; highlights that the polluter pays principle should apply, primarily covering the manufacturing process, but also incentivising better prescription practices and consumer behaviour;

Amendment

5. Considers that a holistic approach, including all the actors concerned, is needed to tackle the negative impact of pharmaceutical products in the environment, taking into account the entire life cycle of drugs; stresses that regulatory actions have to be taken in line with the precautionary principle; highlights that the polluter pays principle should apply at all stages of the life cycle of pharmaceutical products, covering, primarily but not exclusively, the manufacturing process, but also incentivising better prescription practices and consumer behaviour;

Or. fr

Amendment 86  
Jan Huitema, Ulrike Müller

Draft motion for a resolution  
Paragraph 5

Draft motion for a resolution

5. Considers that a holistic approach is needed to tackle pharmaceutical pollution, taking into account the entire life cycle of drugs; stresses that regulatory actions have to be taken in line with the precautionary principle; highlights that the

Amendment

5. Considers that a multistakeholder approach is needed to tackle pharmaceutical pollution, taking into account the entire life cycle of medicines; stresses that regulatory actions have to be taken in line with the precautionary
polluter pays principle should apply, primarily covering the manufacturing process, but also incentivising better prescription practices and consumer behaviour; principle; highlights that the polluter pays principle should apply, primarily covering the manufacturing process, but also incentivising better prescription practices and consumer behaviour; **Calls on the Commission to consider the use of extended producer responsibility to decrease the negative impacts of pharmaceuticals on the environment;**

**Amendment 87**

Stanislav Polčák

*Draft motion for a resolution*

**Paragraph 5**

5. Considers that a holistic approach is needed to tackle pharmaceutical pollution, taking into account the entire life cycle of drugs; stresses that regulatory actions *have to be taken* in line with the precautionary principle; highlights that the polluter pays principle should apply, primarily covering the manufacturing process, but also incentivising better prescription practices and consumer behaviour;

**Amendment**

5. Considers that a holistic approach is needed to tackle pharmaceutical pollution, taking into account the entire life cycle of drugs; stresses that, *in order to ensure the effectiveness of the* regulatory actions *being adopted, it is vital that they are adopted* in line with the *prevention principle and the* precautionary principle; highlights, *furthermore,* that the polluter pays principle should apply, primarily covering the manufacturing process, but also incentivising better prescription practices and consumer behaviour;

**Amendment 88**

Anja Hazekamp

*Draft motion for a resolution*

**Paragraph 5**

5. Considers that a holistic approach is
needed to tackle pharmaceutical pollution, taking into account the entire life cycle of drugs; stresses that regulatory actions have to be taken in line with the precautionary principle; highlights that the polluter pays principle should apply, primarily covering the manufacturing process, but also incentivising better prescription practices and consumer behaviour;

needed to tackle pharmaceutical pollution at source, taking into account the entire life cycle of drugs; stresses that regulatory actions have to be taken in line with the precautionary principle and the control at source principle; highlights that the polluter pays principle should apply, primarily covering entire lifecycle of pharmaceuticals from the manufacturing process to prescription, and from use to disposal and waste treatment;

Amendment 89
Maria Spyrraki, Vangelis Meimarakis, Elissavet Vozemberg-Vrionidi, Georgios Kyrtos, Anna-Michelle Asimakopoulou

Draft motion for a resolution
Paragraph 5

5. Considers that a holistic approach is needed to tackle pharmaceutical pollution, taking into account the entire life cycle of drugs; stresses that regulatory actions have to be taken in line with the precautionary principle; highlights that the polluter pays principle should apply, primarily covering the manufacturing process, but also incentivising better prescription practices and consumer behaviour;

5. Considers that a multi-stakeholder approach is needed to tackle the impacts of pharmaceuticals in the environment, taking into account the entire life cycle of drugs by designing and implementing a policy mix that combines source-directed, use-oriented and end-of-pipe-measures using a combination of voluntary, economic and regulatory instruments; and also incentivizing better prescription practices and consumer behaviour;

Amendment 90
Cristian-Silviu Buşoi

Draft motion for a resolution
Paragraph 5

Draft motion for a resolution

Amendment
5. Considers that a holistic approach is needed to tackle pharmaceutical pollution, taking into account the entire lifecycle of drugs; stresses that regulatory actions have to be taken in line with the precautionary principle; highlights that the polluter pays principle should apply, primarily covering the manufacturing process, but also incentivising better prescription practices and consumer behaviour;

5. Considers that a multi stakeholder and coordinated approach is needed to tackle the negative impacts of pharmaceuticals in the environment, taking into account the entire lifecycle of medicines by designing and implementing a policy mix that combines source-directed, use-oriented and end-of-pipe-measures using a combination of voluntary, economic and regulatory instruments;

Or. en

Amendment 91
Tudor Ciuhodaru

Draft motion for a resolution
 Paragraph 5 a (new)

Draft motion for a resolution
Amendment

5a. Considers it necessary to organise, in collaboration with the Member States, campaigns to inform and educate the public about the dangers of over-consumption of non-prescribed medicines; draws attention to the increase in the number of supermarket and online sales of medicines without medical recommendation and to the danger of media advertising for such points of sale outside of pharmacies or suitably accredited establishments;

Or. ro

Amendment 92
Jan Huitema, Ulrike Müller

Draft motion for a resolution
 Paragraph 6

Draft motion for a resolution
Amendment
6. Highlights that emissions of pharmaceuticals into the environment may not only harm ecosystems, but may also undermine the effectiveness of these same pharmaceuticals, as they can cause the emergence of antibiotic resistance;  

Or. en

Amendment 93
Catherine Chabaud

Draft motion for a resolution
Paragraph 6

6. Highlights that emissions of pharmaceuticals into the environment may not only harm ecosystems, but may also undermine the effectiveness of these same pharmaceuticals, especially in the case of antibiotics, as they can cause the emergence of antibiotic resistance;  

Or. en

Amendment 94
Catherine Chabaud

Draft motion for a resolution
Paragraph 6 a (new)

6 a. Recalls that pharmaceuticals have diverse impacts on aquatic and marine ecosystems but also wildlife, including behavioural changes, fecundity reduction, size modification or development of sexual and reproductive abnormalities; calls therefore on the Commission to integrate concrete measures taking into account the cumulative effects of
Amendment 95
Kateřina Konečná

Draft motion for a resolution
Paragraph 7

Draft motion for a resolution

7. Recalls that studies have shown that pharmaceutical products are especially present in water bodies, and that they are ineffectively filtered by wastewater treatment plants;

Amendment

7. Recalls that studies have shown that pharmaceutical products are especially present in water bodies, and that they are ineffectively filtered by wastewater treatment plants currently cannot effectively filter out all pharmaceutical products, due to the intrinsically different chemical properties of the relevant substances;

Or. en

Amendment 96
Catherine Chabaud

Draft motion for a resolution
Paragraph 7

Draft motion for a resolution

7. Recalls that studies have shown that pharmaceutical products are especially present in water bodies, and that they are ineffectively filtered by wastewater treatment plants;

Amendment

7. Recalls that studies have shown that pharmaceutical products are especially present in water bodies, and that they are ineffectively filtered by wastewater treatment plants; highlights that contamination of freshwater and rivers basins naturally lead to contamination of the ocean on a global scale;

Or. en
Amendment 97
Günther Sidl, Tiemo Wölken, Nicolás González Casares, Mohammed Chahim, César Luena, Eric Andrieu, Biljana Borzan, Demetris Papadakis

Draft motion for a resolution
Paragraph 7

7. Recalls that studies have shown that pharmaceutical products are especially present in water bodies, and that *they are ineffectively filtered by* wastewater treatment plants;

Amendment
7. Recalls that studies have shown that pharmaceutical products are especially present in water bodies, and that wastewater treatment plants *currently cannot effectively filter out all pharmaceutical products, due to the intrinsically different chemical properties of the relevant substance*;

Or. en

Amendment 98
Tudor Ciuhodaru

Draft motion for a resolution
Paragraph 7

7. Recalls that studies have shown that pharmaceutical products are especially present in water bodies, and that they are ineffectively filtered by wastewater treatment plants;

Amendment
7. Recalls that studies have shown that pharmaceutical products are especially present in water bodies, and that they are ineffectively filtered by wastewater treatment plants, *requiring periodic adaptation of purification processes in line with the new products and technologies on the market*;

Or. ro

Amendment 99
Jan Huitema, Ulrike Müller

Draft motion for a resolution
Paragraph 7
Draft motion for a resolution

7. Recalls that studies have shown that pharmaceutical products are especially present in water bodies, and that they are **ineffectively filtered by** wastewater treatment plants;

Amendment

7. Recalls that studies have shown that pharmaceutical products and residues are especially present in water bodies, and that they are **not always effectively removed by** wastewater treatment plants;

Or. en

Amendment 100
Nathalie Colin-Oesterlé

Draft motion for a resolution
Paragraph 7

Draft motion for a resolution

7. Recalls that studies have shown that pharmaceutical products **are** especially present in water bodies, and that they **are ineffectively filtered by** wastewater treatment plants;

Amendment

7. Recalls that studies have shown that residue from pharmaceutical products is especially present in water bodies, and that it is **not completely removed by conventional** wastewater treatment plants;

Or. fr

Amendment 101
Alexander Bernhuber

Draft motion for a resolution
Paragraph 7

Draft motion for a resolution

7. Recalls that studies have shown that pharmaceutical products are especially present in water bodies, and that they are ineffectively **filtered by** wastewater treatment plants;

Amendment

7. Recalls that studies have shown that pharmaceutical products are especially present in water bodies, and that they are ineffectively **removed by conventional** wastewater treatment plants;

Or. de

Amendment 102
Michèle Rivasi

Draft motion for a resolution
Paragraph 7

7. Recalls that studies have shown that pharmaceutical products are especially present in water bodies, and that they are ineffectively filtered by wastewater treatment plants;

Amendment

7. Recalls that studies have shown that pharmaceutical products are especially present in water bodies, and that they are ineffectively removed by conventional wastewater treatment plants;

Or. en

Amendment 103
Eleonora Evi, Daniela Rondinelli, Piernicola Pedicini

Draft motion for a resolution
Paragraph 8

8. Notes that due to generally low concentrations, risks are more related to possible cumulative effects of long-term low-dose exposure than to acute or immediate health effects; is particularly concerned by the endocrine disrupting properties of many pharmaceuticals ending up in the environment;

Amendment

8. Notes that due to generally low concentrations in drinking water, risks for human health are more related to possible cumulative effects of long-term low-dose exposure than to acute or immediate health effects; is particularly concerned by the endocrine disrupting properties of many pharmaceuticals ending up in the environment;

Or. en

Amendment 104
Günther Sidl, Tiemo Wölken, Nicolás González Casares, Mohammed Chahim, César Luena, Eric Andrieu, Biljana Borzan, Demetris Papadakis

Draft motion for a resolution
Paragraph 8

8. Notes that due to generally low
concentrations, risks are more related to possible cumulative effects of long-term low-dose exposure than to acute or immediate health effects; is particularly concerned by the endocrine disrupting properties of many pharmaceuticals ending up in the environment;

concentrations, risks for human health are more related to possible cumulative effects of long-term low-dose exposure than to acute or immediate health effects; is particularly concerned by the endocrine disrupting properties of many pharmaceuticals ending up in the environment;

Amendment 105
Jan Huitema, Ulrike Müller
Draft motion for a resolution
Paragraph 8

8. Notes that due to generally low concentrations, risks are more related to possible cumulative effects of long-term low-dose exposure than to acute or immediate health effects; is particularly concerned by the endocrine disrupting properties of many pharmaceuticals ending up in the environment;

Draft motion for a resolution
Amendment

8. Notes that due to generally low concentrations, risks are more related to possible cumulative effects of long-term low-dose exposure than to acute or immediate health effects; is particularly concerned by the endocrine disrupting properties of certain pharmaceuticals ending up in the environment;

Or. en

Amendment 106
Eleonora Evi, Daniela Rondinelli, Piernicola Pedicini
Draft motion for a resolution
Paragraph 9

Draft motion for a resolution
Amendment

9. Points to the need to regulate pharmaceuticals under water legislation; recalls that interinstitutional negotiations are on-going on a review of the Directive on the quality of water intended for human consumption and on a regulation on minimum requirements for water reuse;

9. Points to the need to regulate pharmaceuticals under water legislation; recalls that interinstitutional negotiations are on-going on a review of the Directive on the quality of water intended for human consumption and on a regulation on minimum requirements for water reuse;

Or. en
Believes that pharmaceuticals should be regulated also in relation to soil. On this regard, it is appropriate that the Commission proposes an overview Directive on soil protection in the EU with specific actions on ways to address soil pollution from pharmaceuticals;

Amendment 107
Alexander Bernhuber

Draft motion for a resolution
Paragraph 9

Draft motion for a resolution

9. Points to the need to regulate pharmaceuticals under water legislation; recalls that interinstitutional negotiations are on-going on a review of the Directive on the quality of water intended for human consumption and on a regulation on minimum requirements for water reuse;

Amendment

9. Points to the fact that the impact of pharmaceutical residues on water resources must be taken into account in the review of EU water legislation;

Amendment 108
Rory Palmer, Seb Dance

Draft motion for a resolution
Paragraph 9

Draft motion for a resolution

9. Points to the need to regulate pharmaceuticals under water legislation; recalls that interinstitutional negotiations are on-going on a review of the Directive on the quality of water intended for human consumption and on a regulation on minimum requirements for water reuse;

Amendment

9. Points to the need to regulate pharmaceuticals under water legislation through setting limits for concentration of antibiotic active pharmaceutical ingredients discharged in water; recalls that interinstitutional negotiations are on-going on a review of the Directive on the quality of water intended for human consumption and on a regulation on minimum requirements for water reuse;
consumption and on a regulation on minimum requirements for water reuse;

Or. en

Amendment 109
Michèle Rivasi

Draft motion for a resolution
Paragraph 9

9. Points to the need to regulate pharmaceuticals under water legislation; recalls that interinstitutional negotiations are on-going on a review of the Directive on the quality of water intended for human consumption and on a regulation on minimum requirements for water reuse;

Amendment
9. Calls on the Commission to consider the impact of pharmaceuticals on water resources in the framework of the review of EU water legislation;

Or. en

Amendment 110
Mairead McGuinness

Draft motion for a resolution
Paragraph 9

9. Points to the need to regulate pharmaceuticals under water legislation; recalls that interinstitutional negotiations are on-going on a review of the Directive on the quality of water intended for human consumption and on a regulation on minimum requirements for water reuse;

Amendment
9. Points to the need to regulate pharmaceuticals under water legislation and notes that specific pharmaceuticals are regulated under the Water Framework Directive; recalls that interinstitutional negotiations are on-going on a review of the Directive on the quality of water intended for human consumption and on a regulation on minimum requirements for water reuse;

Or. en
Amendment 111
Kateřina Konečná

Draft motion for a resolution
Paragraph 9

Draft motion for a resolution

9. Points to the need to regulate pharmaceuticals under water legislation; recalls that interinstitutional negotiations are on-going on a review of the Directive on the quality of water intended for human consumption and on a regulation on minimum requirements for water reuse;

Amendment

9. Points to the need to regulate pharmaceuticals under water legislation; recalls that interinstitutional negotiations are on-going on a review of the Directive on the quality of water intended for human consumption and on a regulation on minimum requirements for water reuse; 

asks that regulation for other compartments such as soils be implemented as well;

Or. en

Amendment 112
Joanna Kopcińska, Jadwiga Wiśniewska

Draft motion for a resolution
Paragraph 9

Draft motion for a resolution

9. Points to the need to regulate pharmaceuticals under water legislation; recalls that interinstitutional negotiations are on-going on a review of the Directive on the quality of water intended for human consumption and on a regulation on minimum requirements for water reuse;

Amendment

9. Points to the need to regulate pharmaceuticals under water legislation; recalls that interinstitutional negotiations are on-going on a review of the Directive on the quality of water intended for human consumption and on a regulation on minimum requirements for water reuse; 

asks that regulation for other compartments such as soils be implemented as well;

Or. en

Amendment 113
9. Points to the need to regulate pharmaceuticals under water legislation; recalls that interinstitutional negotiations are on-going on a review of the Directive on the quality of water intended for human consumption and on a regulation on minimum requirements for water reuse;

9. Recalls that interinstitutional negotiations are on-going on a review of the Directive on the quality of water intended for human consumption and on a regulation on minimum requirements for water reuse;

Amendment 114
Aldo Patriciello

9. Points to the need to regulate pharmaceuticals under water legislation; recalls that interinstitutional negotiations are on-going on a review of the Directive on the quality of water intended for human consumption and on a regulation on minimum requirements for water reuse;

9. Points to take into account that specific pharmaceuticals are already regulated under the Water Framework Directive; recalls the importance of managing pharmaceuticals under the existing framework due to the public health role they serve;

Amendment 115
Günther Sidl, Tiemo Wölken, Nicolás González Casares, Mohammed Chahim, César Luena, Eric Andrieu, Biljana Borzan, Demetris Papadakis
10. Asks for a special focus to be put on emission hot spots, such as hospitals and pharmaceutical production plants;

10. Asks for a special focus to be put on emission hot spots, such as hospitals and pharmaceutical production plants, **in accordance with the control at source principle**, and additional hot spots such as certain wastewater treatment plants;

Or. en

Amendment 116
Kateřina Konečná

Draft motion for a resolution
Paragraph 10

10. Asks for a special focus to be put on emission hot spots, such as hospitals and pharmaceutical production plants;

10. Underlines the need to gather new and more detailed data on emission hot spots, such as hospitals and pharmaceutical production plants, **and the use of digital and big data monitoring systems**;

Or. en

Amendment 117
Dolors Montserrat

Draft motion for a resolution
Paragraph 10

10. Asks for a special focus to be put on emission hot spots, such as hospitals and pharmaceutical production plants;

10. Underlines the need to gather new and more detailed data on emission hot spots, such as hospitals and pharmaceutical production plants, **and the use of digital and big data monitoring systems**;

Or. en

Amendment 118
10. Asks for a special focus to be put on emission hot spots, such as hospitals and pharmaceutical production plants;

10. Asks, with regard to the effectiveness of the measures being adopted, for a special focus to be put on emission hot spots, such as hospitals and pharmaceutical production plants;

Or. cs

Amendment 119
Anja Hazekamp, Kateřina Konečná

10. Asks for a special focus to be put on emission hot spots, such as hospitals and pharmaceutical production plants; and intensive stockbreeding areas;

Or. nl

Amendment 120
Cristian-Silviu Bușoi

10. Asks for a special focus to be put on emission hot spots, such as hospitals and pharmaceutical production plants, and waste water treatment plants;

Or. en
Amendment 121
Michèle Rivasi

Draft motion for a resolution
Paragraph 10

Draft motion for a resolution

10. Asks for a special focus to be put on emission hot spots, such as hospitals and pharmaceutical production plants;

Amendment

10. Asks for a special focus to be put on emission hot spots, such as hospitals, pharmaceutical production plants and waste water treatment plants;

Or. en

Amendment 122
Michèle Rivasi

Draft motion for a resolution
Paragraph 10 a (new)

Draft motion for a resolution

10 a. Calls on the Commission to also consider the impact of pharmaceuticals in the context of the zero-pollution action plan for air, water and soil announced by the Commission for 2021;

Amendment

10 a. Calls on the Commission to also consider the impact of pharmaceuticals in the context of the zero-pollution action plan for air, water and soil announced by the Commission for 2021;

Or. en

Amendment 123
Mohammed Chahim

Draft motion for a resolution
Paragraph 10 a (new)

Draft motion for a resolution

10 a. Calls on the Commission to develop Extended Producer Responsibility (EPR) schemes, in order to finance de pollution measures in line with the
polluter pays principle;

Amendment 124
Tiemo Wölken
Draft motion for a resolution
Paragraph 10 a (new)

10 a. Calls on the Commission to develop Extended Producer Responsibility (EPR) schemes, in order to finance depollution measures in line with the polluter pays principle;

Amendment 125
Anja Hazekamp
Draft motion for a resolution
Paragraph 10 a (new)

10 a. Calls on the Commission to develop Extended Producer Responsibility (EPR) schemes, in order to finance depollution measures in line with the polluter pays principle;

Amendment 126
Michèle Rivasi
Draft motion for a resolution
Paragraph 10 b (new)
10 b. Calls on the Commission to develop Extended Producer Responsibility schemes to help finance necessary measures in line with the polluter pays principle;

Amendment 127
Günther Sidl, Tiemo Wölken, Nicolás González Casares, Mohammed Chahim, César Luena, Eric Andrieu, Biljana Borzan, Demetris Papadakis

Draft motion for a resolution
Paragraph 11

11. Calls on the Commission to facilitate the exchange of existing best practices;
Amendment 129  
Jan Huitema, Ulrike Müller

Draft motion for a resolution  
Paragraph 11

Draft motion for a resolution

11. Calls on the Commission to facilitate the exchange of existing best practices;

Amendment

11. Calls on the Commission to facilitate the exchange of existing best practices among Member States and stakeholders, including initiatives such as iPiE, the Eco-pharmaco-Stewardship (EPS) and the #MedsDisposal campaign;

Amendment 130  
Bartosz Arłukowicz

Draft motion for a resolution  
Paragraph 11

Draft motion for a resolution

11. Calls on the Commission to facilitate the exchange of existing best practices;

Amendment

11. Calls on the Commission to facilitate the exchange of existing best practices, including through raising awareness and promoting the re-use of medicine packaging;

Amendment 131  
Rory Palmer, Seb Dance

Draft motion for a resolution  
Paragraph 11

Draft motion for a resolution

11. Calls on the Commission to

Amendment

11. Calls on the Commission to
facilitate the exchange of existing best practices; facilitate the exchange of existing and promote good practice methods to reduce environmental impacts of manufacturing;

Amendment 132
Cristian-Silviu Buşoi

Draft motion for a resolution
Paragraph 11 a (new)

Draft motion for a resolution Amendment

11 a. Encourages that those existing and self-regulated initiatives should be analysed and, where appropriate, considered as models in future EU initiatives on pharmaceuticals in the environment;

Amendment 133
Jan Huitema, Ulrike Müller

Draft motion for a resolution
Subheading 2

Draft motion for a resolution Amendment

Increase awareness and promote prudent use of pharmaceuticals Increase awareness and promote prevention measures and prudent use of pharmaceuticals;

Amendment 134
Nathalie Colin-Oesterlé

Draft motion for a resolution
Paragraph 12
12. Calls on the Member States to share best practices in the preventive use of antibiotics and to reinforce the ‘One Health Action Plan Against Antimicrobial Resistance’; reaffirms the positions expressed in its resolution of 13 September 2018 on a European One Health Action Plan against Antimicrobial Resistance;

Amendment

12. Calls on the Member States to share best practices in the preventive use of antibiotics and to **apply in full and, if necessary**, reinforce the ‘One Health Action Plan Against Antimicrobial Resistance’; reaffirms the positions expressed in its resolution of 13 September 2018 on a European One Health Action Plan against Antimicrobial Resistance;

Or. fr

Amendment 135
Jan Huitema, Ulrike Müller

Draft motion for a resolution
Paragraph 12

12. Calls on the Member States to share best practices in the preventive use of antibiotics and to **reinforce** the ‘One Health Action Plan Against Antimicrobial Resistance’; reaffirms the positions expressed in its resolution of 13 September 2018 on a European One Health Action Plan against Antimicrobial Resistance;

Amendment

12. Calls on the Member States to share best practices in the preventive use of antibiotics and to **fully implement** the ‘One Health Action Plan Against Antimicrobial Resistance’; reaffirms the positions expressed in its resolution of 13 September 2018 on a European One Health Action Plan against Antimicrobial Resistance;

Or. en

Amendment 136
Jan Huitema, Ulrike Müller

Draft motion for a resolution
Paragraph 13

13. Calls on the Member States and on the Commission to promote awareness-raising campaigns among veterinaries and physicians on the prudent use of antibiotics.

Amendment

13. Calls on the Member States and on the Commission to promote awareness-raising campaigns and training among veterinaries, **pharmacists**, physicians,
Amendment 137
Adam Jarubas

Draft motion for a resolution
Paragraph 13

13. Calls on the Member States and on the Commission to promote awareness-raising campaigns among veterinaries and physicians on the prudent use of pharmaceuticals, particularly of antimicrobials; calls on actors in the pharmaceutical supply chain to contribute to providing to patients with sufficient information on how incorrectly disposed medicines may negatively impact the environment; calls for on-pack labelling in the form of an appropriate pictogramme to inform consumers how to properly dispose of unused medicines; health care professionals and patients on the prudent use of pharmaceuticals, particularly of antimicrobials; calls on actors in the pharmaceutical supply chain to contribute to providing to patients with sufficient information on how incorrectly disposed medicines may negatively impact the environment; calls for on-pack labelling in the form of an appropriate pictogramme and a single unit dose barcoding to inform consumers how to properly use and dispose of unused medicines;

Or. en

Amendment 138
Günther Sidl, Tiemo Wölken, Nicolás González Casares, Mohammed Chahim, César
Draft motion for a resolution
Paragraph 13

13. Calls on the Member States and on the Commission to promote awareness-raising campaigns among veterinaries and physicians on the prudent use of pharmaceuticals, particularly of antimicrobials; calls on actors in the pharmaceutical supply chain to contribute to providing to patients with sufficient information on how incorrectly disposed medicines may negatively impact the environment; calls for on-pack labelling in the form of an appropriate pictogramme to inform consumers how to properly dispose of unused medicines;

Amendment

13. Calls on the Member States and on the Commission to promote awareness-raising campaigns and training courses among veterinaries, physicians and pharmacists on the prudent use of pharmaceuticals, such as antimicrobials, antidepressants or contrast fluids; calls on actors in the pharmaceutical supply chain to contribute to providing to patients with clear, sufficient information on how incorrectly disposed medicines may negatively impact the environment; calls for on-pack labelling in the form of an appropriate pictogramme to inform consumers how to properly dispose of unused medicines;

Or. en
properly dispose of unused medicines;

Or. fr

Amendment 140
Michèle Rivasi

Draft motion for a resolution
Paragraph 13

13. Calls on the Member States and on the Commission to promote awareness-raising campaigns among veterinaries and physicians on the prudent use of pharmaceuticals, particularly of antimicrobials; calls on actors in the pharmaceutical supply chain to contribute to providing to patients with sufficient information on how incorrectly disposed medicines may negatively impact the environment; calls for on-pack labelling in the form of an appropriate pictogramme to inform consumers how to properly dispose of unused medicines;

Or. en

Amendment 141
Joanna Kopcińska, Jadwiga Wiśniewska

Draft motion for a resolution
Paragraph 13

13. Calls on the Member States and on the Commission to promote awareness-raising campaigns among veterinaries, physicians and pharmacists on the prudent use of pharmaceuticals, particularly of antimicrobials and antidepressants; calls on actors in the pharmaceutical supply chain to contribute to providing to patients with sufficient information on how incorrectly disposed medicines may negatively impact the environment; calls for on-pack labelling in the form of an appropriate pictogramme to inform consumers how to properly dispose of unused medicines;
to providing to patients with sufficient information on how incorrectly disposed medicines may negatively impact the environment; calls for on-pack labelling in the form of an appropriate pictogramme to inform consumers how to properly dispose of unused medicines;

to contribute to providing to patients with sufficient information on how incorrectly disposed medicines may negatively impact the environment; calls for on-pack labelling in the form of an appropriate pictogramme to inform consumers how to properly dispose of unused medicines;

Or. en

Amendment 142
Anja Hazekamp, Kateřina Konečná

Draft motion for a resolution
Paragraph 13

13. Calls on the Member States and on the Commission to promote awareness-raising campaigns among veterinaries and physicians on the prudent use of pharmaceuticals, particularly of antimicrobials; calls on actors in the pharmaceutical supply chain to contribute to providing to patients with sufficient information on how incorrectly disposed medicines may negatively impact the environment; calls for on-pack labelling in the form of an appropriate pictogramme to inform consumers how to properly dispose of unused medicines;

13. Calls on the Member States and on the Commission to promote awareness-raising campaigns among veterinaries and physicians on the prudent use of pharmaceuticals, particularly of antimicrobials; calls on actors in the pharmaceutical supply chain to contribute to providing to patients and stockbreeders with sufficient information on how incorrectly disposed medicines may negatively impact the environment; calls for on-pack labelling in the form of an appropriate pictogramme to inform consumers how to properly dispose of unused medicines;

Or. nl

Amendment 143
Tudor Ciuhodaru

Draft motion for a resolution
Paragraph 13 a (new)

13a. Stresses that health professionals
must be kept continuously up to date regarding the latest developments in research and good practices when it comes to preventing the spread of AMR;

Or. ro

Amendment 144
Esther de Lange

Draft motion for a resolution
Paragraph 13 a (new)

13 a. Calls on Member States to include the issue of pharmaceuticals in the environment in their cross-border cooperation in river basins, and to coordinate measures where they are deemed useful;

Or. en

Amendment 145
Jan Huitema, Ulrike Müller

Draft motion for a resolution
Paragraph 13 a (new)

13 a. Calls on the Commission and Member States to promote vaccination as a disease prevention measure, to minimise the need of pharmaceuticals;

Or. en

Amendment 146
Tudor Ciuhodaru

Draft motion for a resolution
Paragraph 14

Draft motion for a resolution

14. Highlights the importance of the design, development and manufacturing phases to minimise the environmental impact of pharmaceuticals;

Amendment

14. Highlights the importance of more rapid, ambitious and targeted measures to reduce the environmental risks posed by pharmaceuticals, while acknowledging the need for further research for a better understanding of the extent of the current impact of pharmaceuticals on human health and the environment;

Or. ro

Amendment 147
Kateřina Konečná

Draft motion for a resolution
Paragraph 14

Draft motion for a resolution

14. Highlights the importance of the design, development and manufacturing phases to minimise the environmental impact of pharmaceuticals;

Amendment

14. Highlights the importance of the design, development and manufacturing phases to minimise the environmental impact of pharmaceuticals; has the opinion that the Good Manufacturing Practice (GMP) legislation should be revised to include requirements for environmental protection;

Or. en

Amendment 148
Inese Vaidere

Draft motion for a resolution
Paragraph 14

Draft motion for a resolution

14. Highlights the importance of the design, development and manufacturing phases to minimise the environmental impact of pharmaceuticals;

Amendment

14. Highlights the importance of the design, development and manufacturing phases to minimise the environmental impact of pharmaceuticals;
impact of pharmaceuticals;  
impact of pharmaceuticals, *meanwhile avoiding the price increase for the pharmaceuticals products*;

Or. en

**Amendment 149**  
Rory Palmer, Seb Dance

**Draft motion for a resolution**  
**Paragraph 14 a (new)**

*Draft motion for a resolution*  
**Amendment**

14 a. *Notes that, in relation to the healthcare sector, addressing any excessive workforce pressures on physicians is a necessary condition for healthcare professionals to ensure appropriate prescribing of antimicrobials; further notes that healthcare professionals could be further assisted via the provision of clear, evidence-based prescribing guidance that provides consistent advice across different clinical indications;*

Or. en

**Amendment 150**  
Esther de Lange

**Draft motion for a resolution**  
**Paragraph 15**

*Draft motion for a resolution*  
**Amendment**

15. *Calls on Member States and the Commission to support the development of pharmaceuticals intrinsically less harmful for the environment (‘greener pharmaceuticals’), which degrade more readily, into harmless substances, in wastewater treatment plants and the environment; taking into account that*
greater biodegradability could potentially impair the efficacy and shelf life of medicines, and make it harder to administer precise dosages;

Amendment 151
Nathalie Colin-Oesterlé

Draft motion for a resolution
Paragraph 15

15. Calls on Member States and the Commission to support research, development and innovation of pharmaceuticals which are equally effective for patients and less harmful for the environment (‘greener pharmaceuticals’), which degrade more readily, into harmless substances, in wastewater treatment plants and the environment; calls on the Member States and the Commission to boost funding for this;

Amendment 152
Maria Spyraki, Vangelis Meimarakis, Elissavet Vozemberg-Vrionidi, Georgios Kyrtos, Anna-Michelle Asimakopoulou

Draft motion for a resolution
Paragraph 15

15. Calls on Member States and the Commission to support the development of pharmaceuticals intrinsically less harmful for the environment (‘greener pharmaceuticals’), which degrade more readily, into harmless substances, in wastewater treatment plants and the environment;
wastewater treatment plants and the environment;

Amendment 153
Cristian-Silviu Buşoi

Draft motion for a resolution
Paragraph 15

15. Calls on Member States and the Commission to support the development of pharmaceuticals intrinsically less harmful for the environment (‘greener pharmaceuticals’), which degrade more readily, into harmless substances, in wastewater treatment plants and the environment;

Amendment

15. Calls on Member States and the Commission to support and set financial incentives for research and development of pharmaceuticals intrinsically less harmful for the environment, by reducing, as far as possible, the pharmaceutical characteristics that affect environmental risks such as ecotoxicity, persistence, mobility and bioaccumulation;

Amendment 154
Jan Huitema, Ulrike Müller

Draft motion for a resolution
Paragraph 15

15. Calls on Member States and the Commission to support the development of pharmaceuticals intrinsically less harmful for the environment (‘greener pharmaceuticals’), which degrade more readily, into harmless substances, in wastewater treatment plants and the environment;

Amendment

15. Calls on Member States and the Commission to support research and development of pharmaceuticals intrinsically less harmful for the environment (‘greener pharmaceuticals’), by reducing, as far as possible, the pharmaceutical characteristics that affect environmental risks;
Amendment 155
Jessica Polfjärd

Draft motion for a resolution
Paragraph 15

15. Calls on Member States and the Commission to support the development of pharmaceuticals *intrinsically less harmful for the environment* (‘greener pharmaceuticals’), which degrade more readily, into harmless substances, in wastewater treatment plants and the environment;

Amendment

15. Calls on Member States and the Commission to support the development of pharmaceuticals *with a smaller environmental footprint, inter alia by degrading* more readily, into harmless substances, in wastewater treatment plants and the environment;

Or. en

Amendment 156
Nathalie Colin-Oesterlé

Draft motion for a resolution
Paragraph 15 a (new)

15a. Calls on the Member States and all stakeholders concerned to make use of EU programmes to invest in technology aimed at improving the effectiveness of the disposal of pharmaceutical products and antimicrobial-resistant genes whilst ensuring that such products are just as effective in terms of meeting patients' needs;

Amendment

15a. Calls on the Member States and all stakeholders concerned to make use of EU programmes to invest in technology aimed at improving the effectiveness of the disposal of pharmaceutical products and antimicrobial-resistant genes whilst ensuring that such products are just as effective in terms of meeting patients' needs;

Or. fr

Amendment 157
Silvia Sardone, Aldo Patriciello

Draft motion for a resolution
Paragraph 16
16. Considers that the environmental impacts of pharmaceuticals could be included into the benefit-risk assessment of human medicines, as is already the case for veterinary medicines; deleted

Or. it

Amendment 158
Cristian-Silviu Bușoi

Draft motion for a resolution
Paragraph 16

16. Considers that the environmental impacts of pharmaceuticals could be included into the benefit-risk assessment of human medicines, as is already the case for veterinary medicines; deleted

Or. en

Amendment 159
Alessandra Moretti

Draft motion for a resolution
Paragraph 16

16. Considers that the environmental impacts of pharmaceuticals could be included into the benefit-risk assessment of human medicines, as is already the case for veterinary medicines; 16. Considers that the environmental impacts of pharmaceuticals could be included into the benefit-risk assessment of human medicines, as is already the case for veterinary medicines, while making sure that no delay occurs in the marketing authorization procedure of drugs deemed suitable in accordance with the current criteria of the assessment itself, so as to guarantee prompt access to safe and effective pharmacological treatments for
16. Considers that the environmental impacts of pharmaceuticals could be included into the benefit-risk assessment of human medicines, as is already the case for veterinary medicines;

16. Considers that the environmental impacts of new and existing pharmaceutical substances should be included into the benefit-risk assessment of human medicines, as is already the case for veterinary medicines; emphasises that metabolites, degradation products and cocktail effects of pharmaceutical substances should also be considered therein;

Amendment 161
Simona Baldassarre, Silvia Sardone

Draft motion for a resolution
Paragraph 16

16. Considers that the environmental impacts of pharmaceuticals could be included into the benefit-risk assessment of human medicines, as is already the case for veterinary medicines;

16. Considers that the environmental impacts of pharmaceuticals could be included into the benefit-risk assessment of human medicines by drawing up multiple comparative environmental risk assessment tables without compromising access to safe and effective pharmacological treatments;
Amendment 162
Günther Sidl, Tiemo Wölken, Nicolás González Casares, Mohammed Chahim, César Luena, Eric Andrieu, Biljana Borzan, Demetris Papadakis

Draft motion for a resolution
Paragraph 16

16. Considers that the environmental impacts of pharmaceuticals could be included into the benefit-risk assessment of human medicines, as is already the case for veterinary medicines;

Amendment

16. Considers that the environmental impacts of pharmaceuticals shall be included into the benefit-risk assessment of human medicines, as is already the case for veterinary medicines; Metabolites, degradation products and cocktail effects of pharmaceutical substances shall also be considered therein;

Or. en

Amendment 163
Michèle Rivasi

Draft motion for a resolution
Paragraph 16

16. Considers that the environmental impacts of pharmaceuticals could be included into the benefit-risk assessment of human medicines, as is already the case for veterinary medicines;

Amendment

16. Considers that the environmental impacts of pharmaceuticals should be included into the benefit-risk assessment of human medicines, as is already the case for veterinary medicines and calls on the Commission to make a legislative proposal accordingly;

Or. en

Amendment 164
Nicolae Ștefănuță

Draft motion for a resolution
Paragraph 16
16. Considers that the environmental impacts of pharmaceuticals could be included into the benefit-risk assessment of human medicines, as is already the case for veterinary medicines;

16. Calls on the Commission to make a legislative proposal to include the environmental impacts of pharmaceuticals that are not deemed essential, into the benefit-risk assessment of human medicines, as is already the case for veterinary medicines;

Or. en

Amendment 165
Eleonora Evi, Daniela Rondinelli, Piernicola Pedicini

Draft motion for a resolution
Paragraph 16

16. Considers that the environmental impacts of pharmaceuticals could be included into the benefit-risk assessment of human medicines, as is already the case for veterinary medicines;

16. Considers it inappropriate to include the environmental impacts of pharmaceuticals into the benefit-risk assessment of human medicines when it comes to ensuring that patients have access to safe and effective medicines.
pharmaceutical treatments;

Amendment 167
Jan Huitema
Draft motion for a resolution
Paragraph 16

16. Considers that the environmental impacts of pharmaceuticals could be included into the benefit-risk assessment of human medicines, as is already the case for veterinary medicines;

Or. en

Amendment 168
Michèle Rivasi
Draft motion for a resolution
Paragraph 16 a (new)

16 a. Considers that the environmental assessment of pharmaceuticals should encompass their degradation products and metabolites;

Or. en

Amendment 169
Michèle Rivasi
Draft motion for a resolution
Paragraph 16 b (new)
16 b. Considers that pharmaceuticals that are harmful to the environment should only be available upon prescription;

Amendment 170
Nicolae Ștefănuță

Draft motion for a resolution
Paragraph 17

Draft motion for a resolution
17. Calls the Commission to take into account, where appropriate, ongoing existing efforts by stakeholders for future initiatives to reduce environmental risks and promote environmentally responsible practices;

Amendment
17. Calls the Commission to take into account, where appropriate, ongoing existing efforts by stakeholders for future initiatives to reduce environmental risks promote environmentally responsible practices and appropriate use and return of pharmaceuticals;

Amendment 171
Tudor Ciuhodaru

Draft motion for a resolution
Paragraph 18

Draft motion for a resolution
18. Calls for monitoring data from the Water Framework Directive to be used for post-market evaluation;

Amendment
18. Calls for monitoring data from the Water Framework Directive to include suitable parameters regarding the impact of pharmaceuticals that must be used for post-market evaluation;

Amendment 172
Michèle Rivasi
Draft motion for a resolution
Paragraph 19

19. Calls on the Commission to ensure that the emission of pharmaceuticals to water is considered as a possible Key Environmental Issue when reviewing Best Available Techniques Reference Documents under the Industrial Emissions Directive for relevant sectors;

Amendment

19. Calls on the Commission to ensure that the emission of pharmaceuticals to water is considered as a Key Environmental Issue when reviewing Best Available Techniques Reference Documents under the Industrial Emissions Directive for relevant sectors;

Or. en

Amendment 173
Michèle Rivasi

Draft motion for a resolution
Paragraph 19 a (new)

19. a. Furthermore calls on the Commission to include intensive farming into the next review of the Industrial Emissions Directive;

Amendment

19 a. Furthermore calls on the Commission to include intensive farming into the next review of the Industrial Emissions Directive;

Or. en

Amendment 174
Nathalie Colin-Oesterlé

Draft motion for a resolution
Paragraph 20

20. Points to the important role of procurement policy in promoting greener pharmaceuticals; calls on the Commission to develop clear guidance on this issue;

Amendment

20. Points to the important role of procurement policy in promoting pharmaceuticals which respect the environment; calls on the Commission to develop clear guidance on this issue by including, for example, environmental...
criteria in addition to simple economic criteria;

Amendment 175
Jan Huitema, Ulrike Müller

Draft motion for a resolution
Paragraph 20

Draft motion for a resolution

20. Points to the important role of procurement policy in promoting greener pharmaceuticals; calls on the Commission to develop clear guidance on this issue;

Amendment

20. Points to the important role of procurement policy in promoting pharmaceuticals that are intrinsically less harmful for the environment; calls on the Commission to develop clear guidance on this issue;

Amendment 176
Esther de Lange

Draft motion for a resolution
Paragraph 20

Draft motion for a resolution

20. Points to the important role of procurement policy in promoting greener pharmaceuticals; calls on the Commission to develop clear guidance on this issue;

Amendment

20. Points to the important role of procurement policy in promoting pharmaceuticals with low intrinsic toxicity for the environment; calls on the Commission to develop clear guidance on this issue;

Amendment 177
Michèle Rivasi

Draft motion for a resolution
Paragraph 20

*Draft motion for a resolution*

20. Points to the important role of procurement policy in promoting greener pharmaceuticals; calls on the Commission to develop clear guidance on this issue;

*Amendment*

20. Points to the important role of procurement policy in promoting greener pharmaceuticals *in design and manufacturing*; calls on the Commission to develop clear guidance on this issue;

Or. en

Amendment 178
Joanna Kopcińska, Jadwiga Wiśniewska

*Draft motion for a resolution*

Paragraph 20

*Draft motion for a resolution*

20. Points to the important role of procurement policy in promoting greener pharmaceuticals; calls on the Commission to develop clear guidance on this issue;

*Amendment*

20. Points to the important role of procurement policy in promoting greener pharmaceuticals *in design and manufacturing*; calls on the Commission to develop clear guidance on this issue;

Or. en

Amendment 179
Günther Sidd, Tiemo Wölken, Nicolás González Casares, Mohammed Chahim, César Luena, Eric Andrieu, Biljana Borzan, Demetris Papadakis

*Draft motion for a resolution*

Paragraph 20

*Draft motion for a resolution*

20. Points to the important role of procurement policy in promoting greener pharmaceuticals; calls on the Commission to develop clear guidance on this issue;

*Amendment*

20. Points to the important role of procurement policy in promoting greener pharmaceuticals *in design and manufacturing*; calls on the Commission to develop clear guidance on this issue;

Or. en
Amendment 180
Cristian-Silviu Buşoi

Draft motion for a resolution
Paragraph 21 a (new)

Draft motion for a resolution

21 a. Calls on the Commission to include compulsory environmental criteria in the Good Manufacturing Practice (GMP) framework to give EU inspectors the ability to control manufacturing discharges at overseas pharmaceutical factories supplying the EU market;

Or. en

Amendment 181
Günther Sidl, Tiemo Wölken, Nicolás González Casares, Mohammed Chahim, César Luena, Eric Andrieu, Biljana Borzan, Demetris Papadakis

Draft motion for a resolution
Paragraph 21 a (new)

Draft motion for a resolution

21 a. Calls on the Commission to include compulsory environmental criteria in the Good Manufacturing Practice (GMP) framework to give EU inspectors the ability to control manufacturing discharges at overseas pharmaceutical factories supplying the EU market;

Or. en

Amendment 182
Michèle Rivasi

Draft motion for a resolution
Paragraph 21 a (new)

Draft motion for a resolution

Amendment

21 a. Calls on the Commission to take all necessary action so that compulsory environmental criteria are included in the Good Manufacturing Practice (GMP) framework;

Or. en

Amendment 183
Dolors Montserrat

Draft motion for a resolution
Paragraph 21 a (new)

Draft motion for a resolution

Amendment

21 a. Calls on the European Medicines Agency to facilitate joint inspections of manufacturing discharges at overseas pharmaceuticals factories supplying the EU;

Or. en

Amendment 184
Eleonora Evi, Daniela Rondinelli, Piernicola Pedicini

Draft motion for a resolution
Paragraph 22

Draft motion for a resolution

Amendment

22. Considers that a clear road map for completing environmental risk assessments is needed, where those are not available;

22. Considers that a clear road map for completing environmental risk assessments is needed, where those are not available, in particular for those medicinal products which were authorised before 2006 and were not subject to an Environmental Risk assessment in their market authorisation process;
Amendment 185
Stanislav Polčák

Draft motion for a resolution
Paragraph 22

22. Considers that a clear road map for completing environmental risk assessments is needed, where those are not available;

22. Considers that a clear road map for completing environmental risk assessments on pharmaceuticals placed on the EU market is needed, where such assessments are not available;

Amendment 186
Cristian-Silviu Buşoi

Draft motion for a resolution
Paragraph 22

22. Considers that a clear road map for completing environmental risk assessments is needed, where those are not available;

22. Calls on the Commission to initiate a systematic catching-up procedure for medicinal products for human use authorised without an environmental risk assessment;

Amendment 187
Michèle Rivasi

Draft motion for a resolution
Paragraph 22

22. Considers that a clear road map for completing environmental risk assessments

22. Calls on the Commission to swiftly set up a clear road map for completing
is needed, where those are not available; environmental risk assessments for medicinal products for human use in the short term;

Amendment 188
Eleonora Evi, Daniela Rondinelli, Piernicola Pedicini

Draft motion for a resolution
Paragraph 22 a (new)

Draft motion for a resolution
Amendment

22 a. Calls on the Commission to include compulsory environmental criteria in the Good Manufacturing Practice (GMP) framework to give the possibility to EU inspectors to control discharges of third countries pharmaceutical factories supplying the EU;

Amendment 189
Kateřina Konečná

Draft motion for a resolution
Paragraph 22 a (new)

Draft motion for a resolution
Amendment

22 a. Calls on the Commission to include compulsory environmental criteria in the Good Manufacturing Practice (GMP) framework to give EU inspectors the ability to control manufacturing discharges at overseas pharmaceutical factories supplying the EU market;

Or. en
Amendment 190
Tudor Ciuhodaru

Draft motion for a resolution
Paragraph 24

24. Considers it appropriate that pharmaceutical companies submit a joint environmental risk assessment per active substance so as to have coherent information, avoid duplication of work and reduce animal testing;

Amendment

24. Considers it appropriate that pharmaceutical companies submit a joint environmental risk assessment per active substance, including the time necessary for the disappearance of these substances from the environment, based on half-life calculations for radioactive substances, so as to have coherent information, avoid duplication of work and reduce animal testing;

Or. ro

Amendment 191
Jan Huitema, Ulrike Müller

Draft motion for a resolution
Paragraph 24

24. Considers it appropriate that pharmaceutical companies submit a joint environmental risk assessment per active substance so as to have coherent information, avoid duplication of work and reduce animal testing;

Draft motion for a resolution

24. Considers it appropriate that pharmaceutical companies perform a joint environmental risk assessment for similar products where appropriate so as to have coherent information, avoid duplication of work and reduce animal testing; Recalls the Commission is due to evaluate the feasibility of setting up an EU-wide active substance-based review system by 28 January 2022;

Amendment

Recalls the Commission is due to evaluate the feasibility of setting up an EU-wide active substance-based review system by 28 January 2022;

Or. en

Amendment 192
Eleonora Evi, Daniela Rondinelli
Draft motion for a resolution
Paragraph 24

24. Considers it appropriate that pharmaceutical companies submit a joint environmental risk assessment per active substance so as to have coherent information, avoid duplication of work and reduce animal testing;

24. Considers it appropriate that pharmaceutical companies submit a joint environmental risk assessment per active substance so as to have coherent information, avoid duplication of work and make concrete steps towards a complete phase out of animal testing;

Or. en

Amendment 193
Michèle Rivasi

Draft motion for a resolution
Paragraph 24 a (new)

24 a. Calls for an update of the requirements with regard to the environmental risk assessment to ensure a proper environmental risk assessment of all relevant pharmaceuticals based on latest available science, to ensure a proper assessment of persistent, bioaccumulative and toxic substances, that additive effects as well as mixture effects are fully taken into consideration, as well as the risk of development of antibiotic resistance;

Or. en

Amendment 194
Joëlle Mélin, Annika Bruna, Catherine Griset, Luisa Regimenti

Draft motion for a resolution
Paragraph 24 a (new)
24a. Asks the Commission and the Member States quickly to address the lack of studies on the mutual potentiation of the different molecules and the interaction of natural metabolic degradation products;

Or. fr

Amendment 195
Dolors Montserrat

25 a. Calls on the Commission to support research on the assessment of mixture effects, chronic exposition on low dose and antimicrobial resistance development, especially in relation to vulnerable groups of population;

Or. en

Amendment 196
Jessica Polfjärd

26. Stresses that measures must be based on scientific evidence and calls on all relevant players to ensure that actions taken do not jeopardise access to safe and effective pharmaceutical treatments for human patients and animals; in this regard, supports the Commission’s intention to reduce waste by allowing that medicines be dispensed in quantities better matching
needs, including by optimising the package size, and to explore the possibility to extend expiry dates for medicines to avoid that medicines that can still be safely used are unnecessarily thrown away; 

needs, whilst ensuring compliance with current traceability legislation, including by optimising the package size, and to explore the possibility to extend expiry dates for medicines to avoid that medicines that can still be safely used are unnecessarily thrown away;

Amendment 197
Dolors Montserrat

Draft motion for a resolution
Paragraph 26

26. Stresses that measures must be based on scientific evidence and calls on all relevant players to ensure that actions taken do not jeopardise access to safe and effective pharmaceutical treatments for human patients and animals; in this regard, supports the Commission’s intention to reduce waste by allowing that medicines be dispensed in quantities better matching needs, including by optimising the package size, and to explore the possibility to extend expiry dates for medicines to avoid that medicines that can still be safely used are unnecessarily thrown away;

Amendment
26. Stresses that measures must be based on scientific evidence and calls on all relevant players to ensure that actions taken do not jeopardise access to safe and effective pharmaceutical treatments for human patients and animals; in this regard, supports the Commission’s intention to reduce waste by allowing that medicines be dispensed in quantities better matching needs, including by optimising the package size, and to explore the possibility to safely extend expiry dates for medicines to avoid that medicines that can still be safely used are unnecessarily thrown away;

Amendment 198
Anja Hazekamp, Kateřina Konečná

Draft motion for a resolution
Paragraph 26

26. Stresses that measures must be based on scientific evidence and calls on

Amendment
26. Stresses that measures must be based on scientific evidence and calls on

the precautionary principle
all relevant players to ensure that actions taken do not jeopardise access to safe and effective pharmaceutical treatments for human patients and animals; in this regard, supports the Commission’s intention to reduce waste by allowing that medicines be dispensed in quantities better matching needs, including by optimising the package size, and to explore the possibility to extend expiry dates for medicines to avoid that medicines that can still be safely used are unnecessarily thrown away;
calls on all relevant players to ensure that actions taken do not jeopardise access to safe and effective pharmaceutical treatments for human patients and animals; in this regard, supports the Commission’s intention to reduce waste by allowing that medicines be dispensed in quantities better matching needs, including by optimising the package size, and to explore the possibility to extend expiry dates for medicines to avoid that medicines that can still be safely used are unnecessarily thrown away;

Or. nl

Amendment 199
Kateřina Konečná
Draft motion for a resolution
Paragraph 26 a (new)

Draft motion for a resolution

26 a. Calls for an update of the requirements with regard to the environmental risk assessment to ensure a proper assessment of mixture effects and take into account the risk for the development of antimicrobial resistance in the environment;

Or. en

Amendment 200
Dolors Montserrat
Draft motion for a resolution
Paragraph 27

Draft motion for a resolution

27. Considers that the overall per capita drug consumption should be reduced, without jeopardising patients’ health; is of 27. Considers that the overall per capita drug consumption should be reduced, without causing difficulties in the access
the opinion that the overall per animal veterinary medicines consumption should also decrease; to medicines and not reducing the effectiveness of treatments; is of the opinion that the overall per animal veterinary medicines consumption should also decrease and better alternatives should be found;

Amendment 201
Anja Hazekamp

Draft motion for a resolution
Paragraph 27

Draft motion for a resolution

27. Considers that the overall per capita drug consumption should be reduced, without jeopardising patients’ health; is of the opinion that the overall per animal veterinary medicines consumption should also decrease;

27. Considers that the overall per capita drug consumption should be reduced, without jeopardising patients’ health; is of the opinion that the overall per animal veterinary medicines consumption should also decrease and that intensive stockbreeding should be run down;

Or. nl

Amendment 202
Maria Spyraiki, Vangelis Meimarakis, Elissavet Vozemberg-Vrionidi, Georgios Kyrtos, Anna-Michelle Asimakopoulou

Draft motion for a resolution
Paragraph 27

Draft motion for a resolution

27. Considers that the overall per capita drug consumption should be reduced, without jeopardising patients’ health; is of the opinion that the overall per animal veterinary medicines consumption should also decrease;

27. Considers that pharmaceutical consumption should be monitored transparently in order to support and encourage responsible use of medicines based on evidence in order to avoid over-consumption; is of the opinion that the overall per animal veterinary medicines consumption should also decrease;
Amendment 203
Joanna Kopcińska, Jadwiga Wiśniewska

Draft motion for a resolution
Paragraph 27

Draft motion for a resolution

27. Considers that the overall per capita drug consumption should be reduced, without jeopardising patients’ health; is of the opinion that the overall per animal veterinary medicines consumption should also decrease;

Amendment

27. Considers that the overall per capita drug consumption should be reduced, without jeopardising patients’ health; is of the opinion that the overall per animal veterinary medicines consumption should also decrease without compromising animal health and welfare;

Or. en

Amendment 204
Jan Huitema, Ulrike Müller

Draft motion for a resolution
Paragraph 27

Draft motion for a resolution

27. Considers that the overall per capita drug consumption should be reduced, without jeopardising patients’ health; is of the opinion that the overall per animal veterinary medicines consumption should also decrease;

Amendment

27. Considers that the overall per capita drug consumption should be reduced, without jeopardising patients’ health; is of the opinion that the overall per animal veterinary medicines consumption should also decrease without compromising animal health and welfare;

Or. en

Amendment 205
Christine Schneider, Alexander Bernhuber

Draft motion for a resolution
Paragraph 27
Draft motion for a resolution

27. Considers that the overall *per capita* drug consumption should be reduced, without jeopardising *patients’ health*; is of the opinion that the overall per animal veterinary *medicines consumption* should also decrease;

Amendment

27. Considers that the overall *per capita* drug consumption should be reduced, without jeopardising *patients’ health*; is of the opinion that the overall per animal veterinary *medicines consumption* should also decrease *without compromising animal health and welfare*;

Or. en

Amendment 206
Adam Jarubas

Draft motion for a resolution
Paragraph 27

Draft motion for a resolution

27. Considers that the overall per capita drug consumption *should* be reduced, *without jeopardising patients’ health*; is of the opinion that the overall per animal veterinary *medicines consumption* should also decrease;

Amendment

27. Considers that citizens, carers and healthcare professionals should do a responsible use of medicines, enhancing *health literacy and patient empowerment*, so that the overall per capita drug consumption *could* be reduced;

Or. en

Amendment 207
Nicolae Ştefănuță

Draft motion for a resolution
Paragraph 27 a (new)

Draft motion for a resolution

27 a. Calls for measurable targets to be put into place with the aim of reducing overall prescription and consumption of pharmaceuticals both in human and animal veterinary;

Amendment

Or. en
Amendment 208
Adam Jarubas

Draft motion for a resolution
Paragraph 27 a (new)

Draft motion for a resolution

27 a. Is of the opinion that further efforts are needed to decrease the overall per animal veterinary medicines consumption;

Or. en

Amendment 209
Jan Huitema, Ulrike Müller

Draft motion for a resolution
Paragraph 28

Draft motion for a resolution

28. Considers that a review of Directive 86/278/EEC on sewage sludge is long overdue; calls on the Commission to make a legislative proposal to review and update Directive 86/278/EEC no later than by the end of 2020, not least so as to avoid that pharmaceutical residues are spread onto fields;

28. Considers that a review of Directive 86/278/EEC on sewage sludge is long overdue; calls on the Commission to make a legislative proposal to review and update Directive 86/278/EEC no later than by the end of 2020, in order to update quality standards according to the latest scientific evidence to promote a true circular economy which does not harm human health and the environment;

Or. en

Amendment 210
Adam Jarubas

Draft motion for a resolution
Paragraph 28

Draft motion for a resolution

Amendment
28. Considers that a review of Directive 86/278/EEC on sewage sludge is long overdue; calls on the Commission to make a legislative proposal to review and update Directive 86/278/EEC no later than by the end of 2020, not least so as to avoid that pharmaceutical residues are spread onto fields;

Amendment 211
Nathalie Colin-Oesterlé

Draft motion for a resolution
Paragraph 28

Draft motion for a resolution

28. Considers that a review of Directive 86/278/EEC on sewage sludge is long overdue; calls on the Commission to make a legislative proposal to review and update Directive 86/278/EEC no later than by the end of 2020, not least so as to avoid that pharmaceutical residues are spread onto fields;

Amendment

28. Considers that a review of Directive 86/278/EEC on sewage sludge is long overdue; calls on the Commission to evaluate and eventually revise Directive 86/278/EEC no later than by the end of 2021, in order to update quality standards according to the latest scientific evidence to promote true circular economy of carbon and nutrients without risk to human health or the environment;

Or. en

Amendment 212
Günther Sidl, Tiemo Wölken, Nicolás González Casares, Mohammed Chahim, César Luena, Eric Andrieu, Biljana Borzan

Draft motion for a resolution
Paragraph 28 a (new)

Draft motion for a resolution

28 a. Emphasises that the affordability of water has to be maintained and costly

Amendment

28 a. Emphasises that the affordability of water has to be maintained and costly
treatment plant upgrades should not be shifted to consumers; therefore takes the view that financing depollution via wastewater charges would only burden citizens and would not provide any incentive to reduce the input of pollutants during the manufacturing procedure;

Amendment 213
Kateřina Konečná

Draft motion for a resolution
Paragraph 29

29. Considers that pharmaceutical production plants should pre-treat their wastewater;

Amendment

29. Considers that pharmaceutical production plants should pre-treat their wastewater; request in this context that the relevant authorities set monitoring requirements to the industry as well as stricter limits to the concentrations of pharmaceuticals in the wastewater ending up to the municipal WWTPs;

Or. en

Amendment 214
Stanislav Polčák

Draft motion for a resolution
Paragraph 29

29. Considers that pharmaceutical production plants should pre-treat their wastewater;

Amendment

29. Considers that pharmaceutical production plants should pre-treat their wastewater in accordance with the principle of preventing environmental threats, especially at source;

Or. cs
Amendment 215
Jan Huitema
Draft motion for a resolution
Paragraph 29

Draft motion for a resolution
Amendment

29. Considers that pharmaceutical production plants should pre-treat their wastewater;

29. Considers that pharmaceutical production plants should pre-treat their wastewater, according to the Best Available Techniques;

Or. en

Amendment 216
Günther Sidl, Tiemo Wölken, Nicolás González Casares, Mohammed Chahim, César Luena, Eric Andrieu, Biljana Borzan
Draft motion for a resolution
Paragraph 29

Draft motion for a resolution
Amendment

29. Considers that pharmaceutical production plants should pre-treat their wastewater;

29. Considers that pharmaceutical production plants should pre-treat their wastewater, applying Best Available Techniques;

Or. en

Amendment 217
Michèle Rivasi
Draft motion for a resolution
Paragraph 29

Draft motion for a resolution
Amendment

29. Considers that pharmaceutical production plants should pre-treat their wastewater;

29. Considers that pharmaceutical production plants should pre-treat their wastewater applying Best Available Techniques;
Amendment 218  
Cristian-Silviu Buşoi  

Draft motion for a resolution  
Paragraph 29

Draft motion for a resolution

29. Considers that pharmaceutical production plants should pre-treat their wastewater;  

Amendment

29. Considers that pharmaceutical production plants should pre-treat their wastewater applying best available techniques;  

Amendment 219  
Anja Hazekamp  

Draft motion for a resolution  
Paragraph 30

Draft motion for a resolution

30. Calls for full enforcement of the existing provisions with regard to take-back schemes for unused medicines;  

Amendment

30. Calls for full enforcement of the existing provisions with regard to take-back schemes for unused medicines and calls on Member States which have not yet set up these provisions to do so;  

Amendment 220  
Nathalie Colin-Oesterlé  

Draft motion for a resolution  
Paragraph 30

Draft motion for a resolution

30. Calls for full enforcement of the existing provisions with regard to take-back schemes;  

Amendment

30. Calls for the Member States to implement and fully enforce the existing provisions with regard to take-back schemes;
back schemes for unused medicines;  

Amendment 221  
Bartosz Arłukowicz  

Draft motion for a resolution  
Paragraph 30

Draft motion for a resolution  
Amendment

30. Calls for full enforcement of the existing provisions with regard to take-back schemes for unused medicines;  

30. Calls for full enforcement of the existing provisions with regard to take-back schemes for unused medicines and for the widest possible promotion of this type of solution;  

Amendment 222  
Jan Huitema, Ulrike Müller  

Draft motion for a resolution  
Paragraph 30

Draft motion for a resolution  
Amendment

30. Calls for full enforcement of the existing provisions with regard to take-back schemes for unused medicines;  

30. Calls on the Member States to set up and fully enforce the existing provisions with regard to take-back schemes for unused medicines;  

Amendment 223  
Cristian-Silviu Bușoi  

Draft motion for a resolution  
Paragraph 30

Draft motion for a resolution  
Amendment
30. Calls **for full enforcement of the existing** provisions with regard to take-back schemes for unused medicines;

30. Calls **on Member States to set up and fully enforce** provisions with regard to take-back schemes for unused medicines;

Or. en

**Amendment 224**
Adam Jarubas

Draft motion for a resolution
Paragraph 30

**Draft motion for a resolution**

30. Calls **for full enforcement of the existing** provisions with regard to take-back schemes for unused medicines;

**Amendment**

30. Calls **on Member States to set up and fully enforce** provisions with regard to take-back schemes for unused medicines;

Or. en

**Amendment 225**
Günther Sidl, Tiemo Wölken, Nicolás González Casares, Mohammed Chahim, César Luena, Eric Andrieu, Biljana Borzan, Demetris Papadakis

Draft motion for a resolution
Paragraph 30

**Draft motion for a resolution**

30. Calls **for full enforcement of the existing** provisions with regard to take-back schemes for unused medicines;

**Amendment**

30. Calls **on Member States to set up and enforce** provisions with regard to take-back schemes for unused medicines;

Or. en

**Amendment 226**
Esther de Lange

Draft motion for a resolution
Paragraph 30

**Draft motion for a resolution**

30. Calls **for full enforcement of the existing** provisions with regard to take-back schemes for unused medicines;

**Amendment**

30. Calls **on Member States to set up and enforce** provisions with regard to take-back schemes for unused medicines;

Or. en
30. Calls for full enforcement of the existing provisions with regard to take-back schemes for unused medicines;

30. Calls on Member States to set up and enforce provisions with regard to take-back schemes for unused medicines;

Or. en

Amendment 227
Mohammed Chahim

Draft motion for a resolution
Paragraph 31 a (new)

Draft motion for a resolution

Amendment

31 a. Calls on the Commission and Member States to fund research and innovation in more advanced water treatment technologies that can improve the removal of pharmaceutical residues and other substances;

Or. en

Amendment 228
Kateřina Konečná

Draft motion for a resolution
Paragraph 31 a (new)

Draft motion for a resolution

Amendment

31 a. Recalls that the Commission is due to evaluate the feasibility of setting up an EU-wide active substance-based review system by 28 January 2022 and calls on the Commission to make a legislative proposal to adopt such a review system;

Or. en

Amendment 229
Jan Huitema, Ulrike Müller
Draft motion for a resolution
Paragraph 31 a (new)

31 a. Calls on the Commission and Member States to support research, innovation and development of more advanced waste water treatment technologies that can detect and improve the removal of pharmaceutical residues;

Or. en

Amendment 230
Tudor Ciuhodaru

Draft motion for a resolution
Paragraph 32

32. Is concerned that monitoring of pharmaceuticals in the environment is still very limited; stresses the need to strengthen post-marketing control mechanisms into comprehensive monitoring, also with regard to environmental effects, as the current surveillance system (pharmacovigilance) is not adequately and systematically covering the environmental data deficit;

Or. ro

Amendment 231
Silvia Sardone, Aldo Patriciello

Draft motion for a resolution
Paragraph 32

32. Is concerned that monitoring of pharmaceuticals in the environment is still very limited; stresses the need to strengthen post-marketing control mechanisms through comprehensive monitoring, with the introduction of new indicators where necessary, including environmental impact monitoring, as the current surveillance system (pharmacovigilance) is not adequately and systematically covering the environmental data deficit;

Or. ro
32. Is concerned that monitoring of pharmaceuticals in the environment is still very limited; stresses the need to strengthen post-marketing control mechanisms into comprehensive monitoring, also with regard to environmental effects, as the current surveillance system (pharmacovigilance) is not adequately and systematically covering the environmental data deficit;

32. Is concerned that monitoring of pharmaceuticals in the environment is still very limited; stresses the need to strengthen post-marketing control mechanisms and environmental monitoring, in order to ensure adequate and systematic scrutiny of the environmental data deficit;

Amendment 232
Maria Spyriaki, Vangelis Meimarakis, Elissavet Vozemberg-Vrionidi, Georgios Kyrtos, Anna-Michelle Asimakopoulou

Draft motion for a resolution
Paragraph 32

Draft motion for a resolution

32. Is concerned that monitoring of pharmaceuticals in the environment is still very limited; stresses the need to strengthen post-marketing control mechanisms into comprehensive monitoring, also with regard to environmental effects, as the current surveillance system (pharmacovigilance) is not adequately and systematically covering the environmental data deficit;

32. Is concerned that monitoring of pharmaceuticals in the environment is still very limited; stresses the need to strengthen post-marketing control mechanisms such as environmental monitoring, to adequately and systematically cover the environmental data deficit;

Or. en

Amendment 233
Jan Huitema, Ulrike Müller, Fredrick Federley

Draft motion for a resolution
Paragraph 32

Draft motion for a resolution

32. Is concerned that monitoring of pharmaceuticals in the environment is still very limited; stresses the need to strengthen post-marketing control mechanisms into comprehensive monitoring, also with regard to environmental effects, as the current surveillance system (pharmacovigilance) is not adequately and systematically covering the environmental data deficit;

32. Is concerned that monitoring of pharmaceuticals in the environment is still very limited; stresses the need to strengthen post-marketing control mechanisms such as environmental monitoring, to adequately and systematically cover the environmental data deficit;
very limited; stresses the need to strengthen post-marketing control mechanisms into comprehensive monitoring, also with regard to environmental effects, as the current surveillance system (pharmacovigilance) is not adequately and systematically covering the environmental data deficit;

Amendment 234
Michèlle Rivasi

Draft motion for a resolution
Paragraph 32

32. Is concerned that monitoring of pharmaceuticals in the environment is still very limited; stresses the need to strengthen post-marketing control mechanisms into comprehensive monitoring, also with regard to environmental effects, as the current surveillance system (pharmacovigilance) is not adequately and systematically covering the environmental data deficit;

Or. en

Amendment 235
Eleonora Evi, Daniela Rondinelli, Piernicola Pedicini

Draft motion for a resolution
Paragraph 32

32. Is concerned that monitoring of pharmaceuticals in the environment, in particular in soil, is still very limited; stresses the need to strengthen post-marketing control mechanisms into comprehensive monitoring, also with regard to environmental effects, as the current surveillance system (pharmacovigilance) is not adequately and systematically covering the environmental data deficit;

Or. en
mechanisms into comprehensive monitoring, also with regard to environmental effects, as the current surveillance system (pharmacovigilance) is not adequately and systematically covering the environmental data deficit;

control mechanisms into comprehensive monitoring, also with regard to environmental effects, as the current surveillance system (pharmacovigilance) is not adequately and systematically covering the environmental data deficit;

**Amendment 236**

Joanna Kopcińska, Jadwiga Wiśniewska

**Draft motion for a resolution**

**Paragraph 32**

32. Is concerned that monitoring of pharmaceuticals in the environment is still very limited; stresses the need to strengthen post-marketing control mechanisms into comprehensive monitoring, also with regard to environmental effects, as the current surveillance system (pharmacovigilance) is not adequately and systematically covering the environmental data deficit;

32. Is concerned that monitoring of pharmaceuticals in the environment, notably in soil, is still very limited; stresses the need to strengthen post-marketing control mechanisms into comprehensive monitoring, also with regard to environmental effects, as the current surveillance system (pharmacovigilance) is not adequately and systematically covering the environmental data deficit;

**Amendment 237**

Eleonora Evi, Daniela Rondinelli, Piernicola Pedicini

**Draft motion for a resolution**

**Paragraph 33**

33. Calls on the Commission to address the possible impact of pharmaceuticals on the watchlist pursuant to the Water Framework Directive and to assess whether the list should be updated;

33. Calls on the Commission to address the possible impact of pharmaceuticals on the watchlist pursuant to the Water Framework Directive and to assess whether the list should be updated, in particular by including all pharmaceuticals for which an environmental risk has been identified.
during the authorisation process and by monitoring data in relation to Predicted No Effect Concentration (PNEC) to identify where mitigation measures would be necessary;

Amendment 238
Anja Hazekamp, Kateřina Konečná

Draft motion for a resolution
Paragraph 33

Draft motion for a resolution
33. Calls on the Commission to address the possible impact of pharmaceuticals on the watchlist pursuant to the Water Framework Directive and to assess whether the list should be updated;

Amendment
33. Calls on the Commission to address the possible impact of pharmaceuticals on the watchlist pursuant to the Water Framework Directive and to assess whether the list should be updated; calls on the Commission to propose a soil framework directive, focusing in particular on the concentration of antibiotics in the soil;

Or. nl

Amendment 239
Eleonora Evi, Daniela Rondinelli, Piernicola Pedicini

Draft motion for a resolution
Paragraph 33 a (new)

Draft motion for a resolution
33 a. Calls on the Commission to include pharmaceuticals that pose a significant risk to the environment in the list of priority substances under the Water Framework Directive and set environmental quality standards and concentration limits under the Environmental Quality Standards (EQS) Directive;

Amendment

33 a. Calls on the Commission to include pharmaceuticals that pose a significant risk to the environment in the list of priority substances under the Water Framework Directive and set environmental quality standards and concentration limits under the Environmental Quality Standards (EQS) Directive;
Amendment 240
Günther Sidl, Tiemo Wölken, Nicolás González Casares, Mohammed Chahim, César Luena, Eric Andrieu, Biljana Borzan, Demetris Papadakis

Draft motion for a resolution
Paragraph 33 a (new)

Draft motion for a resolution

Amendment

33 a. Calls on the Commission to include pharmaceuticals that pose a significant risk to the environment in the list of priority substances under the Water Framework Directive and set environmental quality standards and concentration limits under the Environmental Quality Standards (EQS) Directive;

Amendment

33 a. Calls on the Commission to include pharmaceuticals that pose a significant risk to the environment in the list of priority substances under the Water Framework Directive and set environmental quality standards and concentration limits under the Environmental Quality Standards Directive;

Or. en
Amendment 242
Anja Hazekamp, Kateřina Konečná

Draft motion for a resolution
Paragraph 34

34. Highlights that comprehensive monitoring of antibiotics has been developed in farming; calls on the Commission to also develop a monitoring system in relation to human antibiotics;
calls on the Commission to propose a pharmaceuticals monitoring programme, focusing in particular on the concentration of antibiotics in the soil;

Or. nl

Amendment 243
Catherine Chabaud

Draft motion for a resolution
Paragraph 35

35. Emphasises the need to support further research, particularly under the next multi-annual financial framework, on the direct impact on human health of exposure to pharmaceuticals and their residues in the environment and on better understanding how pharmaceuticals enter and persist in the environment,

Or. en

Amendment 244
Kateřina Konečná

Draft motion for a resolution
Paragraph 35
35. Emphasises the need to support further research, particularly under the next multi-annual financial framework, on the direct impact on human health of exposure to pharmaceuticals and their residues in the environment and on better understanding how pharmaceuticals enter and persist in the environment;
multi-annual financial framework, on the direct impact on human health of exposure to pharmaceuticals and their residues in the environment and on better understanding how pharmaceuticals enter and persist in the environment;

multi-annual financial framework, on the direct impact on human health and ecology of exposure to pharmaceuticals and their residues in the environment and on better understanding how pharmaceuticals enter and persist in the environment;

Amendment 247
Günther Sidl, Tiemo Wölken, Nicolás González Casares, Mohammed Chahim, César Luena, Eric Andrieu, Biljana Borzan, Demetris Papadakis

Draft motion for a resolution
Paragraph 35

35. Emphasises the need to support further research, particularly under the next multi-annual financial framework, on the direct impact on human health of exposure to pharmaceuticals and their residues in the environment and on better understanding how pharmaceuticals enter and persist in the environment;

Or. en

Amendment 248
Kateřina Konečná

Draft motion for a resolution
Paragraph 35 a (new)

35 a. Calls on the Commission to include pharmaceuticals that pose a significant risk to the environment in the list of priority substances under the Water Framework Directive and set environmental quality standards and concentration limits under the Environmental Quality Standards (EQS)
Directives;

Amendment 249
Michèle Rivasi

Draft motion for a resolution
Paragraph 36

36. Considers that the methods of analysis to quantify the presence of pharmaceuticals in the environment should be improved;

Amendment
36. Considers that the methods of analysis to quantify the presence of pharmaceuticals in the environment should be improved and that analytical detection methods should be made publicly available;

Amendment 250
Bartosz Arłukowicz

Draft motion for a resolution
Paragraph 36

36. Considers that the methods of analysis to quantify the presence of pharmaceuticals in the environment should be improved;

Amendment
36. Considers that the methods of analysis to quantify the presence of pharmaceuticals in the environment should be improved, as should the development of technologies for this purpose;

Amendment 251
Rory Palmer, Seb Dance

Draft motion for a resolution
Paragraph 36 a (new)
36 a. Considers that, in order to rectify these knowledge gaps, the European Commission should introduce legally binding measures, such as an international treaty on AMR, to stimulate global knowledge sharing and surveillance;

Amendment 252
Nathalie Colin-Oesterlé

Draft motion for a resolution
Paragraph 37

37. Recalls that pharmaceutical environmental information plays a key role for risk management and that this type of information should be made available to relevant stakeholders;

Or. fr

Amendment 253
Günther Sidl, Tiemo Wölken, Nicolás González Casares, Mohammed Chahim, César Luena, Eric Andrieu, Biljana Borzan, Demetris Papadakis

Draft motion for a resolution
Paragraph 37

37. Recalls that pharmaceutical environmental information plays a key role for risk management and that this type of information should be made available to relevant stakeholders; therefore calls on the Commission and the relevant authorities to set up a secure, centralised database enabling all the actors concerned to have access to the results of the environmental risk assessments of products;

Or. fr
for risk management and that this type of information should be made available to relevant stakeholders;

impact on water, environmental behaviour, degradability and possible cocktail effects plays a key role for risk management and that this type of information should be transparent and made available to relevant stakeholders;

Or. en

Amendment 254
Kateřina Konečná

Draft motion for a resolution
Paragraph 37

Draft motion for a resolution

37. Recalls that pharmaceutical environmental information plays a key role for risk management and that this type of information should be made available to relevant stakeholders;

Amendment

37. Recalls that pharmaceutical environmental information such as the impact on water, environmental behaviour, degradability and possible cocktail effects plays a key role for risk management and that this type of information should be transparent and made available to relevant stakeholders;

Or. en

Amendment 255
Anja Hazekamp

Draft motion for a resolution
Paragraph 37

Draft motion for a resolution

37. Recalls that pharmaceutical environmental information plays a key role for risk management and that this type of information should be made available to relevant stakeholders;

Amendment

37. Recalls that pharmaceutical environmental information such as the impact on water, environmental behaviour, degradability and possible cocktail effects plays a key role for risk management and that this type of information should be transparent and made available to relevant stakeholders;
Amendment 256
Michèle Rivasi

Draft motion for a resolution
Paragraph 37

37. Recalls that pharmaceutical environmental information plays a key role for risk management and that this type of information should be made available to relevant stakeholders;

Amendment

37. Recalls that pharmaceutical environmental information plays a key role for risk management and therefore calls on the Commission to make a legislative proposal to make this type of information available to the public and relevant stakeholders;

Amendment 257
Esther de Lange

Draft motion for a resolution
Paragraph 37

37. Recalls that pharmaceutical environmental information plays a key role for risk management and that this type of information should be made available to relevant stakeholders;

Amendment

37. Recalls that pharmaceutical environmental information plays a key role for risk management and that this type of information should be transparent and made available to relevant stakeholders;

Amendment 258
Rory Palmer, Seb Dance

Draft motion for a resolution
Paragraph 39 a (new)
39 a. Calls for the pharmaceutical industry to provide more transparency in supply chains by disclosing origin of drugs and active pharmaceutical ingredients (API) at raw material production stage, to ensure total traceability of all pharmaceutical products;